SEARCH

SEARCH BY CITATION

SUMMARY

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils are pleiotropic multifunctional leukocytes involved in initiation and propagation of diverse inflammatory responses, as well as modulators of innate and adaptive immunity. In this review, the biology of eosinophils is summarized, focusing on transcriptional regulation of eosinophil differentiation, characterization of the growing properties of eosinophil granule proteins, surface proteins and pleiotropic mediators, and molecular mechanisms of eosinophil degranulation. New views on the role of eosinophils in homeostatic function are examined, including developmental biology and innate and adaptive immunity (as well as their interaction with mast cells and T cells) and their proposed role in disease processes including infections, asthma, and gastrointestinal disorders. Finally, strategies for targeted therapeutic intervention in eosinophil-mediated mucosal diseases are conceptualized.


INTRODUCTION

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils are multifunctional leukocytes implicated in the pathogenesis of numerous inflammatory processes including parasitic helminth, bacterial and viral infections, tissue injury, tumor immunity, and allergic diseases (Gleich & Loegering 1984; Weller 1994; Rothenberg 1998). In response to the diverse stimuli, eosinophils are recruited from the circulation into inflammatory foci where they modulate immune responses through an array of mechanisms. Triggering of eosinophils by engagement of receptors for cytokines, immunoglobulins, and complement can lead to the secretion of an array of proinflammatory cytokines, such as interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-16, IL-18, and transforming growth factor (TGF)-α/β, chemokines such as CCL5/RANTES and CCL11/eotaxin-1, and lipid mediators such as platelet-activating factor (PAF) and leukotriene (LT)C4 (Kita 1996). These molecules have proinflammatory effects that include upregulation of adhesion systems, modulation of cellular trafficking and activation and regulation of vascular permeability, mucus secretion, and smooth muscle constriction. Eosinophils can initiate antigen-specific immune responses by acting as antigen-presenting cells. Furthermore, eosinophils can serve as major effector cells inducing tissue damage and dysfunction by releasing toxic granule proteins and lipid mediators (Gleich & Adolphson 1986).

In this chapter, we summarize eosinophil surface marker expression and the growing number of properties defined for eosinophil degranulation. We review the molecular mechanisms involved in eosinophil development and trafficking, including the role of the transcription factors GATA-1, PU.1, and c/EBP members and the eosinophil selective cytokine IL-5 and the eotaxin subfamily of chemokines. Furthermore, we discuss the views on the role of eosinophils in homeostatic function, including developmental biology and innate and adaptive immunity, and in disease processes including infections, asthma, and gastrointestinal disorders.

EOSINOPHIL GRANULE PROTEINS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils contain up to four different populations of secretory organelles: crystalloid granules, primary granules, small granules, and secretory vesicles. The largest of the secretory organelles are the crystalloid granules (0.5–0.8 μm in diameter), which store the majority of granule proteins in eosinophils. The unique crystalloid granules are so called because they contain an intensely staining electron-dense crystalline core surrounded by an electron-lucent matrix when cells are stained and imaged by electron microscopy. Most of the granule proteins packaged into the crystalloid granules are composed of four highly basic proteins. Major basic protein (MBP) is crystallized in the core of the crystalloid granule, where it accounts for virtually all the protein (Gleich et al. 1973; Lewis et al. 1978). Eosinophil peroxidase (EPO), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN) reside in the granule matrix (Egesten et al. 1986; Peters et al. 1986). The primary granules appear during the promyelocytic stage of eosinophil development and are enriched in Charcot–Leyden crystal (CLC) protein. Small secretory vesicles have also been identified that overlap in their contents with those of small granules, and are packed densely in the cytoplasm of eosinophils. The biology of the major cationic proteins in eosinophils has been reviewed in detail (Gleich & Adolphson 1986; Walsh 2001); their functions are summarized in Table 12.1.

Table 12.1.   Functions of eosinophil cationic granule proteins.
MBP
Toxicity toward helminthic parasites such as schistosomulae of Schistosoma mansoni (Butterworth 1984; Ackerman et al. 1985; Gleich & Adolphson 1986)
Cytotoxicity toward airway epithelium (Frigas et al. 1980; Hastie et al. 1987; Hisamatsu et al. 1990; Furuta et al. 2005)
Bronchoconstriction and hyperresponsiveness on aerosolization in rats and monkeys (Gundel et al. 1991; Coyle et al. 1993; Uchida et al. 1993)
Platelet agonist (Rohrbach et al. 1990)
Activation of complement via classical and alternative pathways (Weiler et al. 1992, 1995)
Antibacterial properties (Lehrer et al. 1989)
Activation of remodeling factors from epithelial cells (Pégorier et al. 2006)
Increased cutaneous vasopermeability (Davis et al. 2003)
Stimulation of signaling pathways and mediator release from mast cells, neutrophils and basophils (Zheutlin et al. 1984; Haskell et al. 1995; Page et al. 1999; Shenoy et al. 2003)
ECP
Ribonuclease activity (100 times less potent than EDN) (Slifman et al. 1986)
Toxicity toward helminthic parasites and mammalian epithelial cells (McLaren et al. 1981; Ackerman et al. 1985)
Bactericidal properties (Lehrer et al. 1989)
Induction of Gordon phenomenon (Durack et al. 1979; Fredens et al. 1982)
Promotion of mast cell degranulation (Zheutlin et al. 1984)
EDN
Weakly toxic for parasites and mammalian cells (Ackerman et al. 1985)
Induction of Gordon phenomenon (Durack et al. 1979)
Antiviral activity in respiratory infection (Rosenberg & Domachowske 2001)
EPO
Toxic for mammalian cells and degradative toward connective tissue via ability to form hypohalous acids (Slungaard & Mahoney 1991; Wang & Slungaard 2006)
Cytotoxicity toward airway epithelium (Brottman et al. 1996; Pégorier et al. 2006)
Bactericidal, membrane lysis, and signaling pathway effects (Wang & Slungaard 2006)
Induction of oxidative damage and mutagenesis of DNA and RNA (Shen et al. 2000; Henderson et al. 2001)

MAJOR BASIC PROTEIN

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

As one of the most highly cationic proteins synthesized by eosinophils, MBP is expressed as two different homologs (MBP1 and MBP2). MBP is a small protein that consists of single polypeptide chain of 117 amino acids, with a molecular mass of 13.8 kDa and a high isoelectric point (>11), which cannot be measured accurately due to its extremely basic nature (Hamann et al. 1991). Its basicity is due to the presence of 17 arginine residues, and it also contains nine cysteine residues that enable it to form disulfide bonds. The cDNA for MBP encodes a pre-prosequence that includes a putative signal peptide and an acidic 90-amino acid prosequence that may serve to neutralize MBP's highly basic charge as it is processed through the Golgi and transported to the granule, where the prosequence is cleaved (Barker et al. 1988; McGrogan et al. 1988; Popken-Harris et al. 1998). MBP is among the most abundant proteins in eosinophils, with as much as 250 pg/cell detected in guinea-pig eosinophils, while comparatively less is found in human eosinophils (5–10 pg/cell). MBP1 can also be detected in basophil granules, although there is considerably less expressed than in eosinophils (Ackerman et al. 1983). Mature eosinophils lose the ability to transcribe mRNA encoding MBP, indicating that all the MBP stored in crystalloid granules is synthesized during early eosinophil development prior to maturation (Popken-Harris et al. 1998).

Plasma concentrations of MBP are elevated in the sera of pregnant women, with a peak 2–3 weeks before parturition. Placental eosinophils are few in numbers, and MBP1 has been shown to be synthesized by placental × cells and placentalsite giant cells (Maddox et al. 1984). MBP2 is exclusively expressed by eosinophils, and may be a more specific marker for elevated eosinophils in patients with eosinophilia than MBP1 (Plager et al. 2006). The classical role of eosinophils in protection against parasitic infections has been supported by the toxicity of MBP against helminthic worms (O'Donnell et al. 1983; Butterworth 1984; Ackerman et al. 1985; Gleich & Adolphson 1986). MBP has also been shown to be cytotoxic to airways and may be at least partly responsible for tissue damage associated with eosinophil infiltration in bronchial mucosa in asthma (Frigas et al. 1980; Hisamatsu et al. 1990; Furuta et al. 2005). The toxic effect of MBP is thought to result from increased membrane permeability through surface charge interactions leading to perturbation of the cell-surface lipid bilayer (Wasmoen et al. 1988).

EOSINOPHIL CATIONIC PROTEIN

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

ECP is a member of a subfamily of ribonuclease (RNase) A multigenes expressed in eosinophils, with approximately 15–25 pg synthesized per cell in human eosinophils. Similarly to MBP, ECP is a single-chain cationic polypeptide with a pI >11. On molecular sizing, ECP displays marked heterogeneity, as a result of differential glycosylation, with a molecular mass ranging between 16 and 21.4 kDa. Two isoforms, ECP-1 and ECP-2, have been identified using heparin Sepharose chromatography (Gleich et al. 1986). The cDNA for ECP encodes a leader sequence of 27 amino acids and a mature protein of 133 amino acids with a calculated molecular mass of 15.6 kDa (Barker et al. 1989; Rosenberg et al. 1989). The amino acid sequence is 66% homologous to EDN and 31% homologous to human pancreatic ribonuclease. ECP does have ribonuclease activity but is 100 times less potent than EDN (Slifman et al. 1986). ECP is bactericidal, promotes degranulation from mast cells, and is toxic to helminthic parasites on its own (Gleich et al. 1986; Lehrer et al. 1989). The mechanism of action of ECP is thought to involve pore formation in target membranes, which is apparently not dependent on its RNase activity (Young et al. 1986). ECP was originally characterized for its ability to elicit the Gordon phenomenon (neurotoxicity causing stiffness, ataxia and paralysis) when injected into the cranial ventricles of rabbits (Durack et al. 1979).

EOSINOPHIL-DERIVED NEUROTOXIN

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

A second member of the RNase A multigene family, EDN, also called EPX (Slifman et al. 1986), is expressed in eosinophils and is less basic than ECP or MBP, with a pI of 8.9 due to a smaller number of arginine residues in its sequence. EDN is a single-chain polypeptide with an observed molecular mass of 18.6 kDa. EDN expression is not restricted to eosinophils, as it is also detected in mononuclear cells and possibly neutrophils. ECP and EDN share high sequence homology of 70% at the amino acid level for the pre-form of both proteins, suggesting that these proteins derived from the same gene during evolutionary development (Hamann et al. 1990). Eosinophils express approximately 10 pg of EDN per cell, with marked variation between individuals. EDN similarly induces the Gordon phenomenon when injected intracranially in laboratory animals (Durack et al. 1979). EDN is also implicated in antiviral activity against respiratory infections (Rosenberg & Domachowske 2001). The gene family expressing ECP and EDN has one of the highest rates of mutation in the primate genome, ranking with those of immunoglobulins, T-cell receptors, and major histocompatibility complex (MHC) classes (Rosenberg et al. 1995). This extreme rate of mutation suggests that evolutionary constraints acting on the ECP/EDN subfamily have promoted the acquisition of a specialized antiviral activity, inferred by the high mutation rates of other genes commonly associated with host protection against viral infection.

EOSINOPHIL PEROXIDASE

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

EPO is a heme-containing haloperoxidase with a high pI (>11) composed of two subunits: a heavy chain of 50–57 kDa and a light chain of 11–15 kDa. EPO has 68% sequence identity to neutrophil myeloperoxidase, suggesting that a peroxidase multigene family may have developed through gene duplication (Ten et al. 1989; Hamann et al. 1991). Eosinophils store approximately 15 pg/cell of EPO. The functional role of EPO is associated with bacterial killing. EPO catalyzes the peroxidative oxidation of halides (such as bromide, chloride, and iodide) and pseudohalides (thiocyanate) present in the plasma together with hydrogen peroxide generated by dismutation of superoxide produced during respiratory burst (Weiss et al. 1986; Mayeno et al. 1989; Thomas et al. 1995). This reaction leads to the formation of bactericidal hypohalous acids, particularly hypobromous acid, under physiologic conditions. Eosinophils are robust producers of extracellular superoxide due to expression of high levels of the enzyme complex that generates superoxide (NADPH oxidase) (Someya et al. 1997) and preferential assembly of the enzyme complex at the cell surface (Lacy et al. 2003).

CYTOKINES

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils can synthesize and secrete at least 35 important inflammatory and regulatory cytokines, chemokines, and growth factors (Table 12.2). Many of these cytokines are potent inducers of immune responses in asthma, eczema, rhinitis, and other inflammatory diseases. Those eosinophilderived cytokines that have been quantified generally appear to be generated in relatively small amounts, suggesting an autocrine, paracrine, or juxtacrine role in regulating the function of the microenvironment. However, in some circumstances, eosinophils are the chief producers of cytokines such as TGF-β, which is linked with tissue remodeling in a variety of eosinophil-associated diseases, such as asthma (Kay et al. 2004). A major distinction in cytokine production between eosinophils and T cells, which generate much larger quantities of cytokines, is that eosinophils store their cytokines intracellularly as preformed mediators. Several eosinophil cytokines have been shown to be stored in crystalloid granules and small secretory vesicles, and possess bioactivity on their release (Lacy & Moqbel 2000). This allows the immediate release of cytokines on eosinophil activation, instead of the several hours or days required to generate cytokines from T cells. For example, release of the chemokine RANTES was shown to occur within 60–120 min of eosinophil stimulation by interferon (IFN)-γ. This was related to rapid mobilization (within 10 min) of RANTES in small secretory vesicles that translocated this chemokine to the cell membrane prior to its release (Fig. 12.1). Cytokines generated by eosinophils are discussed in more detail in several comprehensive reviews (Lacy & Moqbel 1997, 2000; Moqbel & Lacy 1998).

Table 12.2.   Cytokine generation by eosinophils.
CytokineProductsStored protein in resting cells (/106 cells)Intracellular site of storage
Interleukins
Interleukin-1αmRNA, protein
Interleukin-2mRNA, protein6 ± 2 pgCrystalloid granules (core)
Interleukin-3mRNA, protein
Interleukin-4mRNA, protein∼75 ± 20 pgCrystalloid granules (core)
Interleukin-5mRNA, proteinCrystalloid granules (core/matrix?)
Interleukin-6mRNA, protein25 ± 6 pgCrystalloid granules (matrix)
Interleukin-9mRNA, protein
Interleukin-10mRNA, protein−25 pg
Interleukin-11mRNA
Interleukin-12mRNA, protein
Interleukin-13mRNA, protein
Interleukin-16mRNA, protein1.6 ± 0.8 ng
Interleukin-17
Leukemia inhibitory factormRNA, protein
Interferons and others
Interferon (IFN)-γmRNA, protein
Tumor necrosis factor αmRNA, proteinCrystalloid granules (matrix)
Granulocyte–macrophage colony-stimulating factormRNA, protein15.1 ± 0.3 pgCrystalloid granules (core)
Chemokines
Epithelial cell-derived neutrophil activating peptide (ENA-78/CXCL5)mRNA, protein12 ± 2 pg
Eotaxin (CCL11)mRNA, protein19 ± 4 pgCrystalloid granules
Growth-related oncogene (GROα/CXCL1)mRNA, protein
Interleukin-8 (CXCL8)mRNA, protein140 pgCytoplasmic
IFN-γ-inducible protein (IP-10/CXCL10)mRNA, protein
IFN-inducible T-cell alpha chemoattractant (I-TAC/CXCL11)mRNA
Macrophage inflammatory protein 1αmRNA, protein
Monocyte chemoattractant protein 1 (MCP-1/CCL3)Protein
Monokine induced by IFN-γ (MIG/CXCL9)mRNA, protein
MCP-3 (CCL7)mRNA
MCP-4 (CCL13)mRNA
RANTES (CCL5)mRNA, protein72 ± 15 pgCrystalloid granules (matrix) and small secretory vesicles
Growth factors
Heparin-binding epidermal growth factor-like binding protein (HB-EGF-LBP)mRNA
Nerve growth factormRNA, protein4 ± 2 pg
Platelet-derived growth factor, B chainmRNA
Stem cell factormRNA, proteinMembrane, cytoplasm
Transforming growth factor αmRNA, protein22 ± 6 pgCrystalloid granules (matrix) and small secretory vesicles
Transforming growth factor β1mRNA, protein
image

Figure 121.  Human eosinophils stimulated with interferon (IFN)-γ to induce rapid release of RANTES. Cells were stained with antibody to major basic protein (MBP) (red) and antibody to RANTES (green) in a time course study of RANTES mobilization. Yellow indicates colocalization of MBP and RANTES to similar granule compartments, which become distinct as early as 10 min following stimulation with IFN-g (500 U/mL). Unstimulated cells (a) were compared with cells stimulated for (b) 5 min, (c) 10 min, (d) 30 min, (e) 60 min, and (f) 16 hours. Original magnification × 1000.

Download figure to PowerPoint

OTHER EOSINOPHIL-DERIVED MEDIATORS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

A major constituent of the human eosinophil is CLC protein, also known as galectin-10 (Ackerman et al. 2002). CLC is a hydrophobic protein of molecular mass 17.4 kDa that was thought to possess a weak lysophospholipase activity, but instead modulates this by interacting with eosinophil lysophospholipases. It is synthesized at very high levels by eosinophils, and is produced at lesser levels in basophils. CLC possesses strong sequence homology to the carbohydratebinding galectin family of proteins, hence its designation as galectin-10. CLC was first characterized by Charcot and Robin in 1853 for its abundance in sputum and fecal samples from patients with severe respiratory and gastrointestinal eosinophilia. Its release results in the formation of distinct, needle-shaped structures that are colorless, measuring 20–40 μm in length and 2–4 μm across. However, the function of CLC remains obscure.

In addition, the eosinophil contains a number of other granule-stored enzymes whose exact role in eosinophil function has not been defined (Spry 1988). They include acid phosphatase (large amounts of which have been isolated from eosinophils), collagenase, arylsulfatase B, histaminase, phospholipase D, catalase, nonspecific esterases, and vitamin B12-binding protein. Eosinophils are also a source of matrix metalloproteases, which have an important role in cell transmigration and inflammation (Ohno et al. 1997; Okada et al. 1997; Schwingshackl et al. 1999; Gauthier et al. 2003; Wiehler et al. 2004), although much less is produced than from monocytes, macrophages, and neutrophils. The intracellular location of matrix metalloprotease-9 has been localized to perinuclear regions and not the crystalloid granules (Ohno et al. 1997).

EOSINOPHILS EXPRESS SNARE ISOFORMS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Secretory cells from diverse biological systems express components of a fusion complex of membrane-bound proteins known as the SNARE (SNAP Receptor) complex, which is essential for vesicular docking and fusion (Sollner et al. 1993; Sutton et al. 1998). This complex, originally characterized in neuronal cells, is composed of VAMP-1 (vesicle-associated membrane protein, also known as synaptobrevin-1), syntaxin-1, and SNAP-25 (synaptosome-associated protein of 25 kDa). These molecules are categorized into two groups, namely vesicular SNAREs (v-SNAREs), which bind to plasma membrane target SNAREs (t-SNAREs). The SNARE molecules form a coiled-coil structure with four separate α-helices contributed by three different molecules during vesicle docking with the plasma membrane. The binding region associated with the four α-helices is known as the SNARE motif. Fusion of the granule membrane with the plasma membrane is dependent on cytosolic NSF (N-ethylmaleimide-sensitive factor) and α, β, or γ-SNAP (soluble NSF-attachment protein)- mediated disassembly of the SNARE complex (Sollner et al. 1993). Cleavage of SNAREs can occur via clostridial neurotoxins containing zinc endopeptidase activity, particularly tetanus toxin and botulinum toxin serotypes (BoNT/A, B, C, D, E, F, and G). These toxins have been used to characterize the dependency of secretion on SNARE complex formation.

Many SNARE proteins have also been identified in nonneuronal secretory cells including syntaxin-4 and SNAP-23 (Ravichandran et al. 1996), while VAMP-2 expression is distributed between neuronal and nonneuronal tissues (Rossetto et al. 1996). In addition, VAMP-4 (Steegmaier et al. 1999), VAMP-5 (Zeng et al. 1998), and the tetanus toxin-insensitive proteins VAMP-7 (formerly known as tetanus toxin-insensitive VAMP or TI-VAMP) (Galli et al. 1998; Advani et al. 1999; Hibi et al. 2000; Ward et al. 2000) and VAMP-8 have been characterized in nonneuronal tissues (Mullock et al. 2000; Paumet et al. 2000; Polgar et al. 2002).

Eosinophils express VAMP-2, VAMP-7, VAMP-8, syntaxin-4, and SNAP-23 (Feng et al. 2001; Lacy et al. 2001; Logan et al. 2002, 2003, 2006), whereas they do not contain detectable levels of the classical neuronal SNARE proteins (syntaxin-1, SNAP-25, and VAMP-1) (Lacy et al. 1995). Eosinophil VAMP-2 is expressed in a population of small secretory vesicles that store the chemokine RANTES, which translocates to the cell membrane during IFN-γ stimulation (Fig. 12.2) (Lacy et al. 1999, 2001). Immunofluorescence staining showed that syntaxin-4 and SNAP-23 were localized to the cell membrane in eosinophils, where they may function as cognate intracellular receptors for VAMP-2 (Fig. 12.3) (Logan et al. 2002). Inhibition of VAMP-2 binding led to the loss of IgE-induced ECP release in permeabilized eosinophils (Hoffmann et al. 2001). A novel isoform of VAMP, known as tetanus-insensitive VAMP (TI-VAMP, also known as VAMP-7), is a putative vesicular SNARE isoform for regulation of lysosomal fusion (Advani et al. 1999; Ward et al. 2000; Rao et al. 2004). VAMP-7 and VAMP-8 are abundantly expressed in eosinophil crystalloid granules, while VAMP-7 was shown to be required for exocytosis of crystalloid granule as well as small secretory vesicles (Logan et al. 2006). This finding suggests that VAMP-2 and VAMP-7 may play overlapping roles in the release of small secretory vesicles from eosinophils, although their release may be more dependent on VAMP-7 (Fig. 12.4). In summary, SNARE isoforms may play a crucial role in the regulation of granule fusion in eosinophils.

image

Figure 122.  Translocation of VAMP-2 during interferon (IFN)-γ stimulation of human eosinophils. Immunolabeling for VAMP-2 (green) showed moderate colocalization with RANTES (red) in (a) unstimulated eosinophils, but these were strongly colocalized at the cell membrane (arrow) following 5 min of stimulation with IFN-γ 500 U/mL (b). Original magnification × 1000.

Download figure to PowerPoint

image

Figure 123.  Localization of SNAP-23 and syntaxin-4 in eosinophils. (Left panel) Distribution of SNAP-23 at cell membranes (arrow) as well as at an intracellular site that colocalizes with the Golgi apparatus (arrowhead). (Right panel) Antibody to syntaxin-4 shows expression in the cell membrane (arrow) and endoplasmic reticulum (arrowhead). Lower panels indicate differential interference contrast images. Original magnification × 630.

Download figure to PowerPoint

image

Figure 124.  Scheme showing SNARE-dependent exocytotic pathways for crystalloid granules and secretory vesicles in eosinophils.

Download figure to PowerPoint

EOSINOPHIL SURFACE MARKERS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

The first characterization of eosinophil surface molecules demonstrated that eosinophils express a large number of cell-surface markers including adhesion molecules, apoptotic signaling molecules, chemokine, complement and chemotactic factor receptors, cytokine receptors, and immunoglobulin receptors (Gupta et al. 1976; Ebisawa et al. 1995). Since these studies and the discovery of new immune receptors (Toll-like receptors, inhibitory receptors and Siglecs) and development of new reagents, the list has been extended revealing that eosinophils express an array of surface structures that were previously thought to be exclusively expressed by other cell types (Tachimoto & Bochner 2000; Rothenberg & Hogan 2006).

Adhesion molecules

Transmigration of the eosinophil through the vascular endothelium is a multistep process involving rolling, tethering, firm adhesion, and transendothelial migration (Wardlaw et al. 1994; Wardlaw 2000). The initial steps of eosinophil rolling and tethering are regulated by selectins and their counterligands expressed on the endothelium (Ebnet et al. 1996; Wardlaw 1999). Eosinophils have been shown to constitutively express L-selectin, which regulates eosinophil rolling on the endothelium in vivo (Georas et al. 1992; Sriramarao et al. 1994). Ligands for L-selectin include CD34 and MAdCAM-1 expressed endothelium (Berg et al. 1993). Eosinophils also express CD162 (P-selectin glycoprotein ligand-1 or PSGL-1) and sialyl-Lewis × (CD15 s), which interact with E-selectin and P-selectins and regulate eosinophil tethering to endothelium (Symon et al. 1996). The firm adhesion of the eosinophil, and transmigration across the vascular epithelium into tissues is regulated by coordinated interaction between networks involving chemokine and cytokine signaling, eosinophil adhesion molecules (e.g., selectins and integrins), and integrin receptors such as vascular cell adhesion molecule (VCAM)-1, mucosal addressin cell adhesion molecule (MAdCAM)-1 and intercellular adhesion molecule (ICAM)-1 expressed on vascular endothelial cells (Kunkel & Butcher 2002; Hogan et al. 2004). Integrins are heterodimeric surface molecules consisting of an α and β chain and eosinophils express members of the β1 (α4β1 and α6β1), β2 (αLβ2, αMβ2, αXβ2, and αDβ2) and α7 (α4β7) integrin families (Georas et al. 1993; Grayson et al. 1998; Tachimoto & Bochner 2000; Bochner & Schleimer 2001; Tachimoto et al. 2002). These various integrin molecules selectively interact with adhesion receptors (VCAM-1, MAdCAM-1, ICAM-1, -2 and -3, and fibrinogen) expressed on the vascular endothelium.

The specific interaction of cell-surface integrins with adhesion receptors (VCAM-1, MAdCAM-1, ICAM-1, ICAM-2, ICAM-3, and fibrinogen) facilitates eosinophil migration into various tissue compartments during inflammation. For example, eosinophil recruitment to the site of allergic inflammation in the lung and skin is regulated by VLA-4 (α4β1 integrin)/VCAM-1-dependent processes (Weg et al. 1993; Abraham et al. 1994; Nakajima et al. 1994; Pretolani et al. 1994; Gonzalo et al. 1996). Pretreatment of mice with neutralizing monoclonal antibodies against α4 or β1 integrin or genetic deletion of VCAM-1 attenuates eosinophil accumulation in the lung during allergic airways disease (Weg et al. 1993; Abraham et al. 1994; Nakajima et al. 1994; Pretolani et al. 1994; Gonzalo et al. 1996). Recent experimental studies have demonstrated that eosinophil recruitment into different tissue compartments (gastrointestinal tract) is regulated by differential adhesion pathways. For example, eotaxin-1-dependent eosinophil recruitment to the small intestine is MAdCAM-1/α4β7 integrin dependent (Mishra et al. 2002), whereas eosinophil accumulation in the colon is regulated by a β2 integrin pathway (ICAM-1) and can occur independently of α4 and β7 integrin-independent pathways (Forbes et al. 2006).

Chemokine, complement and other chemotactic factor receptors

Experimental investigations have shown eosinophils to constitutively express the chemokine receptors CCR3 and CCR1 (Ponath et al. 1996; Phillips et al. 2003; Elsner et al. 2005). Consistent with this observation, eosinophils respond to CCR1 and CCR3 ligands including macrophage inflammatory protein (MIP)-1α/CCL3, RANTES/CCL5, macrophage chemotactic protein (MCP)-2/CCL8, MCP-3/CCL7 and MCP-4/CCL-13, eotaxin-1/CCL11, eotaxin-2/CCL24 and eotaxin-3/CCL26, and mucosa-associated epithelial chemokine (MEC)/CCL28. Eosinophils have also been shown to express a number of other chemokine receptors including CXCR3, CXCR4, CCR5, CCR6, and CCR8 following activation by IL-5 (Sullivan et al. 1999; Nagase et al. 2000; Oliveira et al. 2002). While chemokines are thought to primarily regulate the migration pattern of eosinophils, they have also been shown to promote eosinophil activation and function (Zimmermann et al. 2003). For example, RANTES/CCL5 and eotaxin-1/CCL11 have been shown to promote cellular activation and modulate respiratory burst in eosinophils (Elsner et al. 1997, 1999).

Cytokine receptors

Three cytokines, IL-3, IL-5, and granulocyte–macrophage colony-stimulating factor (GM-CSF), are particularly important in regulating eosinophil development, and eosinophils have been shown to express the specific cytokine receptor subunit for IL-3 (IL-3Rα, CD123), IL-5 (IL-5Rα, CD125) and GM-CSF (GM-CSFRα, CD116) and also the shared β chain (CD131) (Lopez et al. 1986, 1988; Rothenberg et al. 1988; Takatsu et al. 1994). Functional studies have demonstrated that cytokines including stem cell factor (SCF), IFN-γ, tumor necrosis factor (TNF)-α, IL-4, and IL-9 activate eosinophil functions, suggesting that eosinophils express the c-kit receptor (CD117), IFN-γR α-chain (CDw119), TNF-α receptor types 1 and 2 (CD120a, CD120b), type 1 IL-4 receptor [IL-4R α-chain (CD124) and the common α-chain (CD132)], and the IL-9 receptor [IL-9R α-chain (CD129)/CD132] (Wallen et al. 1991; Yuan et al. 1997; Dubois et al. 1998; Nutku et al. 1999; Hauber et al. 2004). Consistent with these obervations, both the type 1 (CD120a) and type 2 (CD120b) TNF receptors have been identified on human eosinophils by fluorescence-activated cells sorting analysis and immune electron microscopy. Activation of these receptors are thought to promote eosinophil apoptosis (Zeck-Kapp et al. 1994; Zeck-Kapp & Kapp 1995). While eosinophils have been shown to express a number of IFN receptor superfamily members, including receptors for IFN-α, IFN-β, IFN-γ, and IL-10 (Giembycz & Lindsay 1999), only the receptor for IFN-γ (type 2 IFN) has been convincingly identified (Aldebert et al. 1996; Ishihara et al. 1997; Matsuyama et al. 1998; Ochiai et al. 1999). The IL-2 receptor is composed of three polypeptide chains, an α-chain (p55) (CD25), β chain (p75) (CD122), and a γ chain (CD132) that is common to several other cytokine receptors. Experimental investigations have demonstrated that IL-2 induces eosinophil chemotaxis, suggesting that the cognitive receptor for the cytokine was expressed on the eosinophils. This was confirmed by the observation that the IL-2-mediated effects could be blocked by antibodies against IL-2R α chain (p55) and β chain (p75) (Rand et al. 1991).

Complement receptors

Initial studies suggested that eosinophils express complement receptors for C3a and C5a (Daffern et al. 1995; DiScipio et al. 1999); however, more recent studies have revealed that eosinophils also express CR1 (CD35), CR3 (CD11b/CD18), CR4 (CD11c), CD103, and receptors for C1q (Walsh et al. 1990; Giembycz & Lindsay 1999). CR1 is recognized by the complement fragments C3b, C4b, iC3b, and C1q. The expression of CR1 on eosinophils is regulated by certain stimuli, including LTB4, 5-HETE, and 5-HPETE (Fischer et al. 1986). CR3 has also been shown to be expressed on eosinophils: CR3 interacts with a number of ligands including iC3b and ICAM-1, all of which could activate eosinophils resulting in eosinophil priming and degranulation (Koenderman et al. 1991).

Prostaglandin and leukotriene receptors

Clincial and experimental studies have demonstrated that eosinophils express both cysteinyl leukotriene receptors (CysLT1R and CysLT2R), high-affinity prostaglandin (PG)D2 type 2 receptor, and the PAF receptor (Wang et al. 1999; Fujii et al. 2005; Zinchuk et al. 2005). Interestingly, the PGE2 receptor is also expressed by basophils and Th2 cells (and is now designated “chemoattractant receptor Th2 cells” or CRTH2) and appears to comediate Th2 cell and eosinophil/basophil recruitment (Hirai et al. 2001). Both mature eosinophils and immature eosinophil progenitors express CysLT1R, whereas CysLT2R has only been identified on mature eosinophils. Expression of these receptors has been shown to be upregulated on eosinophils from asthmatics during excerbations (Fujii et al. 2005). Notably, CysLT2R expression on eosinophils was selectively greater in nonatopic asthmatics (Fujii et al. 2005). The function of these receptors on eosinophils has not yet been fully defined. However, leukotrienes (LTB4, LTD4, LTE4), PAF, and 5-oxo-6,8,11,14-eicosatetraenoic acid induce eosinophil recruitment, suggesting that they may regulate eosinophil transmigration (Powell et al. 1995; Bandeira-Melo et al. 2000; Ohshima et al. 2002; Shiraishi et al. 2005). Previous reports have also demonstrated that in vitro suppression of cysteinyl leukotriene activity by a CysLT1R antagonist blocks eosinophil differentiation and/or maturation, suggesting that cysteinyl leukotrienes may play a role in eosinophil lineage commitment and maturation (Thivierge et al. 2000). Cysteinyl leukotrienes have also been shown to promote eosinophil release of cytokines including IL-4 (Bandeira-Melo et al. 2002a,b). Eosinophils have also been shown to express high levels of the histamine H4 receptor that mediates eosinophil chemoattraction and activation in vitro (O'Reilly et al. 2002).

Immunoglobulin receptors

Eosinophils express Fc receptors for IgA, IgD, IgG, and IgM (Giembycz & Lindsay 1999). CD32 (FcγRII) is constitutively expressed on resting human eosinophils (Hartnell et al. 1990), and is upregulated by IFN-γ (Hartnell et al. 1992). These receptors not only function as IgG receptors but also appear to have a role in stimulating eosinophil survival, degranulation, and generation of leukotrienes (Cromwell et al. 1988, 1990; Kita et al. 1991; Kim et al. 1999). Eosinophils do not constitutively express FcγRI (CD64) or low-affinity FcγRIII (CD16), although expression can be upregulated by cytokines, IFN-γ, complement (C5a), and PAF (Hartnell et al. 1992). Eosinophils do appear to express IgA receptors (CD89) (Monteiro et al. 1993). Ex vivo studies have demonstrated that eosinophil degranulation can be induced by IgA-coated particles, suggesting that IgA–receptor interaction induces eosinophil degranulation (Abu Ghazaleh et al. 1989). The expression or presence of the low-affinity IgE receptor (CD23) or the high-affinity IgE receptor on eosinophils remains controversial (Kita & Gleich 1997). Some studies suggest that eosinophils bind to IgE (Capron et al. 1985, 1995), although more recent investigations suggest that eosinophils express little if any α or β chains for the high-affinity receptor or the low-affinity CD23 IgE receptor (Ying et al. 1998; Kita et al. 1999; Seminario et al. 1999).

Other cell-surface structures

Eosinophil apoptosis has been shown to be induced by two surface structures, CD95 (first) and CD69 (Matsumoto et al. 1995; Walsh et al. 1996). Eosinophils also to express CD9, CD37, CD52, CD63, CD81, CD82, and CD151 (Ebisawa et al. 1995). Experimental investigations have demonstrated that eosinophils can express antigen to naive CD4+ T cells and promote T-cell proliferation and polarization (Shi et al. 2000, 2004; Shi 2004). Consistent with this observation, eosinophils have also been shown to express MHC class II and the necessary costimulatory signals for T-cell activation and proliferation, including the type 1 interval surface membrane glycoprotein CD40 as well as CD80 and CD86 (Ohkawara et al. 1996; Woerly et al. 1999). The expression of CD80 and CD86 appears to be independently regulated by IL-3 and GM-CSF (Tamura et al. 1996). Human eosinophils have also been shown to express the MHC class II protein human leukocyte antigen (HLA)-DR (Shi 2004). Interestingly, peripheral eosinophils of most normal eosinophilic donors do not express HLA-DR proteins, although sputum eosinophils and bronchoalveolar lavage (BAL) eosinophils from asthmatics have been shown to express HLA-DR (Hansel et al. 1991; Sedgwick et al. 1992). Notably, levels of HLA-DR expression on BAL eosinophils from allergic subjects following segmental challenge were elevated compared with peripheral blood eosinophils, suggesting that recruitment and activation of eosinophils following allergen challenge promotes HLA-DR expression (Sedgwick et al. 1992). HLA-DR expression on eosinophils has been shown to be regulated by IL-3, IL-4, GM-CSF, and IFN-γ (Lucey et al. 1989; Weller et al. 1993).

Inhibitory receptors

The CD2 subfamily of the IgE superfamily includes CD2, CD48 (BLAST1) and BTM1 (CD58), LFA3, CD84, IL-9b, CD150, CD229, and 2B4 (CD244). Recent studies have demonstrated that eosinophils express the CD2 subfamily of receptors, namely CD48 and 2B4 (CD244) (Munitz et al. 2005). CD48 is a glycosylphosphatidylinositol (GPI)-anchored protein involved in cellular activation, costimulation, and adhesion. CD48 expression is elevated on human eosinophils from atopic asthmatics and is upregulated by IL-3 (Munitz et al. 2006). Cross-linking of CD48 on eosinophils triggers eosinophil degranulation (Munitz et al. 2005, 2006). Notably, CD48 is the high-affinity ligand for 2B4. Eosinophils also express inhibitory receptor IRp60/CD300a, p140, Siglec-8, Siglec-10, ILT5/LIR3, CD33, and p75/adhesion inhibitory receptor molecules (Munitz & Levi-Schaffer 2007). IRp60 activation has been shown to be involved in the suppression of eosinophil activation (Munitz et al. 2005). Interestingly, CCR3 has been shown to induce negative signaling in murine eosinophils following receptor engagement with the Th1 chemokine CXCL9 (MIg) (Fulkerson et al. 2005).

Toll-like receptors

Eosinophils express mRNA for a number of Toll-like receptors (TLR) including TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10 (Plotz et al. 2001; Sabroe et al. 2002; Nagase et al. 2003). The level of TLR expression on eosinophils is low relative to other granulocytes such as neutrophils, except for relatively elevated levels of TLR7/TLR8 (Nagase et al. 2003). The natural ligands for TLR7/TLR8 are currently not clear, although significant evidence suggests that guanosine- and uridine-rch ssRNA are physiologic ligands for these TLRs (Heil et al. 2004). Functional analysis using TLR-specific ligands reveals that TLR7/TLR8 ligands (R-848) induced eosinophil activation (superoxide production) and prolonged eosinophil survival. The expression of TLR7/TLR8 has been shown to be regulated by cytokines including IFN-γ (Nagase et al. 2003).

EOSINOPHILS AND IMMUNE REGULATION

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

In recent years, eosinophils have been shown to possess the ability to perform numerous immune functions, including antigen presentation (Shi et al. 2000; MacKenzie et al. 2001) and exacerbation of inflammatory responses through their capacity to release a range of largely preformed cytokines and lipid mediators (Gleich & Adolphson 1986; Weller 1994).

Thymic eosinophils

Eosinophils transmigrate into the thymus during the neonatal period, reaching maximum levels by 2 weeks of age. Interestingly, their absolute levels are approximately equivalent to that of thymic dendritic cells (Throsby et al. 2000). Eosinophils primarily localize to the corticomedullary region of the thymus and reach basal levels by 28 days of age. Subsequently, an increase in thymic eosinophil levels at 16 weeks of age corresponds to the commencement of thymic involution. Notably, eosinophils at this stage localize to the medullary region.

Thymic eosinophils express high levels of MHC class II molecules and moderate levels of MHC class I and the costimulatory molecules CD86 (B7.2) and CD30L (CD153) (Fig. 12.5). Furthermore, thymic eosinophils are CD11b/CD11c double-positive and appear to be activated, as they lose expression of GL-1 and CD62L and upregulate CD25 and CD69 surface expression. Analysis of thymic eosinophil cytokine production reveals that eosinophils express mRNA for the proinflammatory cytokines TNF-α, TGF-β, IL-1α and IL-6 and the Th2 cytokines IL-4 and IL-13 (Throsby et al. 2000). Notably, the recruitment of eosinophils into the thymus is regulated by eotaxin-1, which is constitutively expressed in the thymus (Matthews et al. 1998).

image

Figure 125.  Schematic diagram showing surface molecules expressed by human eosinophils. Molecules have been listed based on convincing evidence for their expression as assessed by flow cytometry or inferred by cellular responsiveness to specific stimuli. Cluster designation (CD) for particular molecules is indicated based on the most recent classification (http://www.ncbi.nlm.nih.gov/prow/).

Download figure to PowerPoint

It has been postulated that eosinophils are associated with MHC class I-restricted thymocyte deletion. Consistent with this notion, the biphasic recruitment of eosinophils and their anatomic localization within discrete compartments of the thymus coincides with negative selection of double-positive thymocytes (Throsby et al. 2000). Employing an experimental model of acute negative selection, increased thymic eosinophil levels have been demonstrated in MHC class I-restricted female H-Y T-cell receptor transgenic mice following cognate peptide injection. In addition, eosinophils are associated with clusters of apoptotic bodies, suggesting eosinophil-mediated MHC class I-restricted thymocyte deletion. Thymic eosinophils have the capacity to promote thymocyte apoptosis as they express costimulatory molecules involved in clonal deletions, such as CD30L (CD153) and CD66 (Throsby et al. 2000). Additionally, eosinophils may induce thymocyte apoptosis via free radicals, as thymic eosinophils express high levels of NADPH oxidase activity; notably, developing thymocytes have increased sensitivity to free radicals due to downregulation of Cu2+/Zn2+ superoxide dismutase.

Antigen presentation

Recent clinical and experimental investigations have shown that eosinophils can function as antigen-presenting cells (Fig. 12.6). Eosinophils are capable of processing and presenting a variety of microbial, viral, and parasitic antigens, as well as superantigens (Shi 2004). GM-CSF-treated eosinophils promote T-cell proliferation in response to staphylococcal superantigen (Staphylococcus enterotoxins A, B and E) stimulation (Mawhorter et al. 1994). Furthermore, eosinophils incubated with human rhinovirus-16 promote rhinovirus-16-specific T-cell proliferation and IFN-γ secretion (Handzel et al. 1998). Eosinophils can also effectively present soluble antigens to CD4+ T cells, thereby promoting T-cell proliferation and polarization. Adoptive transfer of antigen-pulsed eosinophils results in eosinophil-dependent T-cell proliferation (MacKenzie et al. 2001). Furthermore, addition of antigen to eosinophil and T-cell cocultures promotes heightened T-cell proliferative responses (Shi et al. 2000). The capacity of eosinophils to present antigen has been debated in some publications. It is interesting to note that the failure of eosinophils to present antigen may be related to the methods used for isolating eosinophils. For example, lysis of erythrocytes with ammonium chloride, an inhibitor of lysosome acidification (needed for antigen presentation), negatively correlates with eosinophil antigen presentation activity (Shi et al. 2000; van Rijt et al. 2003).

image

Figure 126.  Schematic diagram of an eosinophil and its multifunctional effects. Eosinophils are bilobed granulocytes with eosinophilic staining secondary granules. The secondary granules contain four primary cationic proteins designated eosinophil peroxidase (EPO), major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil derived neurotoxin (EDN). All four proteins are cytotoxic molecules; in addition, ECP and EDN are ribonucleases. Eosinophils respond to diverse stimuli including nonspecific tissue injury, viral infections, allografts, allergens, and tumors. In addition to releasing their preformed cationic proteins, eosinophils can also release a variety of cytokines, chemokines, lipid mediators, and neuromodulators. Eosinophils directly communicate with T cells and mast cells in a bidirectional manner. Eosinophils activate T cells by serving as antigen-presenting cells and eosinophil-derived MBP is a mast cell secretagogue. Eosinophils can also regulate T-cell polarization through synthesis of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in oxidative metabolism of tryptophan, catalyzing the conversion of tryptophan to kynurenines (KYN), a regulator of Th1/Th2 balance. 15-HETE, 15-hydroxyeicosatetraenoic acid; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NGF, nerve growth factor; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T-cell expressed and secreted; SCF, stem cell factor; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal polypeptide. See text for definition of other abbreviations. (Adapted from Rothenberg & Hogan 2006 with permission.)

Download figure to PowerPoint

Eosinophils secrete an array of cytokines capable of promoting T-cell proliferation, and activation of Th1 or Th2 polarization (IL-2, IL-4, IL-6, IL-12, IL-10) (Kita 1996; Lacy & Moqbel 2000; Shi et al. 2000; MacKenzie et al. 2001) (Fig. 12.6 and Table 12.2). Recent attention has been drawn to the ability of murine eosinophils to produce IL-4. Employing mice with enhanced green fluorescent protein (GFP) in the IL-4 gene locus (4get mice), eosinophils appear to be a primary source of IL-4 following parasitic infection or anti-IgD treatment (a strong Th2 stimulator). Notably, while the IL-4 gene locus is transcriptionally active in eosinophils, the amount of IL-4 protein production appears to be lower than in T cells and basophils (Shinkai et al. 2002; Khodoun et al. 2004; Voehringer et al. 2004). Furthermore, murine eosinophils promote IL-4, IL-5, and IL-13 secretion by CD4+T cells (MacKenzie et al. 2001). Eosinophils can also regulate T-cell polarization through their synthesis of indoleamine 2,3-dioxygenase, an enzyme involved in oxidative metabolism of tryptophan, converting tryptophan to kynurenines. Kynurenines regulate Th1 and Th2 imbalance by promoting Th1 cell apoptosis (Odemuyiwa et al. 2004). The eosinophil-mediated T-cell proliferative and cytokine secretion responses are dependent on costimulation. Indeed, blockade of CD80, CD86, and CTLA-4 by neutralizing antibodies inhibits eosinophil-elicited T-cell proliferation and cytokine secretion (Shi 2004).

Fluorescent labeling studies have revealed that eosinophils instilled into the trachea of mice traffic into the draining peritracheal lymph nodes and localize to the T-cell-rich paracortical regions (B-cell zones) within 24 hours (Shi et al. 2000). Employing models of allergic airway disease and gastrointestinal allergy, investigators have demonstrated that inhalation of antigen promotes eosinophil homing to the draining endotracheal lymph nodes and Peyer's patches (Korsgren et al. 1997; Mishra et al. 2000; Hogan et al. 2001; MacKenzie et al. 2001).

Interestingly, a recent investigation suggests that eosinophils can only promote proliferation of effector T cells but not naive T cells (van Rijt et al. 2003). Moreover, eosinophils pulsed with ovalbumin peptide and cocultured with ovalbuminspecific T-cell receptor transgenic T cells (D011.10T cells) induced effector T-cell proliferation; however, when cocultured with naive CD4+T cells, no T-cell proliferation was observed. It is tempting to speculate that eosinophils traffic to draining lymph nodes in order to recruit activated effector T cells and promote proliferation of effector T cells.

Mast cell regulation

A substantial body of literature has emerged demonstrating that eosinophils have the capacity to regulate mast cell function (see Fig. 12.6). Notably, human umbilical cord bloodderived mast cells can be activated by MBP to release histamine, PGD2, GM-CSF, TNF-α, and IL-8 (Piliponsky et al. 2002). The activation of mast cells by MBP elicits not only exocytosis but also eicosanoid generation and cytokine production, both of which are prominent responses following FcɛRI-dependent activation of mast cells (Piliponsky et al. 2002). Incubation of rat peritoneal mast cells with native MBP, EPO, and ECP (but not EDN) results in concentrationdependent histamine release (Zheutlin et al. 1984). Several studies have shown that MBP induces mast cell activation via a similar pathway to that observed with other polybasic compounds such as substance P, compound 48/80, and bradykinin (Piliponsky et al. 2001). Freshly isolated human lung mast cells are resistant to IgE-independent activation; however, highly purified lung mast cells cocultured with human lung fibroblasts are sensitive to IgE-independent activation by MBP (Piliponsky et al. 2002). Interestingly, activation of eosinophils with the mast cell protease chymase promotes production of eosinophil-derived stem cell factor, a critical mast cell growth factor. Eosinophils also produce nerve growth factor (NGF) (Solomon et al. 1998), a cytokine not only involved in survival and functional maintenance of sympathetic neurons but also in immune regulation. For example, NGF promotes mast cell survival and activation (Horigome et al. 1994; Bullock & Johnson 1996). NGF is preformed in eosinophils and acts in an autocrine fashion by activating release of EPO (Solomon et al. 1998). EPO activates rat peritoneal muscles to release histamine, suggesting a role of eosinophil-derived NGF in mast cell–eosinophil interactions. Thus, eosinophils and mast cells communicate in a bidirectional fashion.

EOSINOPHIL DEVELOPMENT

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils are produced in the bone marrow from pluripotent stem cells, which first differentiate into a hybrid precursor with shared properties of basophils and eosinophils, and then into a separate eosinophil lineage (Boyce et al. 1995). Initial studies examining the the eos47 gene (encoding EOS47, the avian ortholog of the mammalian melanotransferrin gene), a gene specifically expressed by bone marrow eosinophils, revealed that a 309-bp promoter region consisting of binding sites for Myb-, Ets-, c/EBP-, and GATA-type transcription factors were responsible for governing lineage-specific expression (McNagny et al. 1998).

More recent investigations have supported these initial observations, demonstrating that eosinophil lineage specification is dictated by the interplay of at least three classes of transcription factors including GATA-1 (a zinc finger family member), PU.1 (an Ets family member), and c/EBP members (CCAAT/enhancer-binding protein family) (Nerlov & Graf 1998; Nerlov et al. 1998; McNagny & Graf 2002). Interestingly, these three transcription factors are expressed in a variety of hematopoietic lineages, although their synergistic mechanism of action in eosinophils promotes lineage specificity. The expression level of PU.1 specifies distinct cell lineage fates, with low levels specifying lymphocytic and high levels myeloid differentiation (De Koter & Singh 2000; Du et al. 2002). In most cell types, GATA-1 and PU.1 antagonize each other, but have synergistic activity in regulating eosinophil lineage specification (and eosinophil granule protein transcription) (Du et al. 2002). The specificity of these factors for eosinophils is conserved across species, for example c/EBP factors and GATA-1 drive differentiation of chicken progenitor cells into eosinophils (McNagny & Graf 2002). Of these transcription factors, GATA-1 is clearly the most important for eosinophil lineage specification as revealed by loss of the eosinophil lineage in mice harboring a targeted deletion of the high-affinity GATA-binding site in the GATA-1 promoter (Yu et al. 2002), and based on eosinophil differentiation experiments in vitro (Hirasawa et al. 2002). In particular, the specific activity of GATA-1 in eosinophils but not other GATA-1-positive lineages (mast cells, megakaryocytes, erythroid cells) appears to be mediated by a high-affinity palindromic (or “double”) GATA site (Du et al. 2002). This double GATA site is present in the downstream GATA-1 promoter and also in the regulatory regions of eosinophil-specific genes, including the eotaxin receptor CCR3, MBP, and the IL-5Rα gene, and accounts for eosinophil-specific gene expression (Zimmermann et al. 2000a; Du et al. 2002; Yu et al. 2002). For example, the tandem double GATA site in the human MBP-P2 promoter is required for both promoter activity in human eosinophil cell lines and for synergistic transactivation by GATA-1 and PU.1 (Du et al. 2002). Previous studies have identified cis-acting sequences (cis elements) as important regulators of GATA-1 expression, particularly a 3-cis-acting sequence known as upstream enhancer HS1/G1HE (HS1) as a major enhancer of GATA-1 expression (McDevitt et al. 1997; Onodera et al. 1997). However, studies have demonstrated that HS1 deletion in mice does not affect eosinophil GATA-1 mRNA expression and eosinophil differentiation (Guyot et al. 2004).

A number of the c/EBP members have also been implicated in the regulation of eosinophil lineage commitment (Nerlov et al. 1998). Phenotypic characterization of c/EBPα-deficient mice revealed that these mice are devoid of eosinophils (Zhang et al. 1997). This is consistent with studies demonstrating eosinophil formation from cord blood progenitors by enforced expression of c/EBPα (Iwama et al. 2002). Collectively these studies suggest that coexpression of GATA-1 and c/EBPα are required for efficient eosinophil formation (Hirasawa et al. 2002; Iwama et al. 2002; McNagny & Graf 2002).

More recent investigations have demontrated that expression of eosinophil granule proteins is also regulated by c/EBPɛ and PU.1. Eosinophils from c/EBPɛ−/− mice have an abnormal phenotype (Yamanaka et al. 1997). Notably, in these mice neutrophil secondary granule gene expression is severely impaired, suggesting that c/EBPɛ may be involved in granule gene expression (Gombart et al. 2003). c/EBPɛ and GATA-1 proteins have been shown to weakly induce MBP expression; however, addition of PU.1 dramatically upregulates endogenous MBP expression, suggesting that PU.1 may regulate eosinophil-specific gene expression (Gombart et al. 2003). Consistent with these observations, MBP and EDN gene expression was attenuated in myeloid cell lines derived from PU.1−/− mice. Furthermore, PU.1 has been shown to be involved in the expression of other eosinophil-specific gene expression including EDN (van Dijk et al. 1998). Granulocytes are generated from a small number of hematopoietic stem cells and this process is highly regulated and maintained at a constant level under steady-state conditions (Metcalf 1991; Tenen et al. 1997; Zhu & Emerson 2002). However, under conditions of inflammation or cytokine stimulation, termed “emergency granulopoiesis,” the hematopoietic system greatly amplifies granulocyte formation. This process has been shown to be regulated by many cytokines (G-CSF, GM-CSF, IL-3). A recent study suggests that c/EBP factors (c/EBPα and c/EBPβ) also play an important role in the regulation of different aspects of steady-state and inflammatory stimuli-induced (emergency) granulopoiesis (Kincade 2006). Employing c/EBPβ-deficient mice, investigators have demonstrated normal steady-state granulopoiesis in the absence of c/EBPβ, suggesting that c/EBPα is sufficient for steady-state granulopoiesis. This has been confirmed by the demonstration of complete loss of granulocytes in c/EBPα-deficient mice (Zhang et al. 1997). Notably, emergency granulopoiesis induced by cytokine stimulation was ablated in c/EBPβ- deficient mice (Hirai et al. 2006), suggesting that c/EBPβ selectively regulates emergency granulopoiesis. In support of this hypothesis, cytokine treatment induced c/EBPβ but not c/EBPα or c/EBPɛ transcripts in granulocyte progenitors. Furthermore, granulocytes can be generated from c/EBPα−/− progenitors following cytokine stimulation in vivo (Hirai et al. 2006). These studies suggest that c/EBPα regulates steadystate and c/EBPβ emergency granulopoiesis (Hirai et al. 2006; Kincade 2006).

Three cytokines, IL-3, IL-5, and GM-CSF, are particularly important in regulating eosinophil development (Lopez et al. 1986, 1988; Rothenberg et al. 1988; Takatsu et al. 1994). These eosinophilopoietins likely provide permissive proliferative and differentiation signals following the instructive signals specified by the transcription factors GATA-1, PU.1, and c/EBPs. These cytokines are encoded by closely linked genes on chromosome 5q31. They bind to receptors that share a common β chain and have unique α chains (Vadas et al. 1994). Of these three cytokines, IL-5 is the most specific to the eosinophil lineage and is responsible for selective differentiation of eosinophils (Sanderson 1992). IL-5 also stimulates the release of eosinophils from the bone marrow into the peripheral circulation (Collins et al. 1995). The critical role of IL-5 in the production of eosinophils is best demonstrated by genetic manipulation of mice. Overproduction of IL-5 in transgenic mice results in profound eosinophilia (Dent et al. 1990; Tominaga et al. 1991; Lee et al. 1997; Mishra et al. 2002) and deletion of the IL-5 gene causes a marked reduction of eosinophils in the blood and lungs after allergen challenge (Foster et al. 1996; Kopf et al. 1996). The overproduction of one or a combination of these three cytokines occurs in humans with eosinophilia, and diseases with selective eosinophilia are often accompanied by overproduction of IL-5 (Owen et al. 1989). The critical role of IL-5 in regulating eosinophils in humans has been demonstrated by several clinical trials with humanized anti-IL-5 antibody; this currently unapproved drug dramatically lowers eosinophil levels in the blood and to a lesser extent in the inflamed lung (Leckie et al. 2000; Flood-Page et al. 2003a; Kips et al. 2003).

EOSINOPHIL TRAFFICKING

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Chemokine regulation of eosinophil and CD4+ T-cell trafficking

Under baseline conditions, most eosinophils traffic into the gastrointestinal tract where they normally reside within the lamina propria of all segments except the esophagus (Mishra et al. 1999). The gastrointestinal eosinophil is the predominant population of eosinophils. Under baseline conditions, eosinophil levels in the gastrointestinal tract occur independent of lymphocytes and enteric flora, indicating unique regulation compared with other leukocytes (Mishra et al. 1999). Indeed, the recruitment of gastrointestinal eosinophils is regulated by the constitutive expression of eotaxin-1, as demonstrated by the marked decrease of this population of eosinophils in eotaxin-1-deficient mice. The importance of eotaxin-1 in regulating the baseline level of eosinophils is reinforced by the observation that mice with targeted deletion of CCR3 (but not eotaxin-2-deficient mice) also have a deficiency in gastrointestinal eosinophils (Humbles et al. 2002; Pope et al. 2005a). In addition to trafficking into the gastrointestinal tract, under homeostatic conditions eosinophils home into the thymus, mammary gland, and uterus, also under the regulation of eotaxin-1 (Gouon-Evans et al. 2000; Rothenberg et al. 2001a). Notably, trafficking into the uterus is regulated by estrogen, as eosinophil and eotaxin-1 levels cycle with estrus (Gouon-Evans & Pollard 2001).

The trafficking of eosinophils into inflammatory sites has been shown to involve a number of cytokines (most notably the Th2 cell products IL-4, IL-5, and IL-13) (Sher et al. 1990a; Moser et al. 1992; Horie et al. 1997), adhesion molecules (e.g., β1, β2, and β7 integrins) (Bochner & Schleimer 1994), chemokines such as RANTES and the eotaxins (Zimmermann et al. 2003), and other recently identified molecules (e.g., acidic mammalian chitinase) (Zhu et al. 2004) (Fig. 12.7). Of the cytokines implicated in modulating leukocyte recruitment, only IL-5 and the eotaxins selectively regulate eosinophil trafficking (Rankin et al. 2000). IL-5 regulates growth, differentiation, activation, and survival of eosinophils and has been shown to provide an essential signal for the expansion and mobilization of eosinophils from the bone marrow into the lung following allergen exposure (Collins et al. 1995). However, antigen-induced tissue eosinophilia can occur independent of IL-5, as demonstrated by residual tissue eosinophils in trials using anti-IL-5 in patients with asthma (Flood-Page et al. 2003a), and by IL-5-deficient mice (Foster et al. 1996; Hogan et al. 1997). Recent studies have demonstrated an important role for the eotaxin subfamily of chemokines in eosinophil recruitment to the lung (Zimmermann et al. 2003).

image

Figure 127.  Schematic representation of eosinophil trafficking. Eosinophils develop in the bone marrow where they differentiate from hematopoietic progenitor cells into mature eosinophils under the control of the critical transcription factors GATA-1, PU.1 and c/EBP members. The eosinophilopoietins IL-3, IL-5, and GM-CSF regulate eosinophil expansion, especially in conditions of hypereosinophilia. Eosinophil migration out of the bone marrow into the circulation is primarily regulated by IL-5. Circulating eosinophils subsequently interact with the endothelium by processes involving rolling, adhesion, and diapedesis. Depending on the target organ, eosinophils cross the endothelium into tissues by a regulated process involving coordinated interaction between networks involving the chemokines, eosinophil adhesion molecules, and adhesion receptors on the endothelium. (Adapted from Rothenberg & Hogan 2006 with permission.)

Download figure to PowerPoint

Eotaxin was initially discovered using a biological assay in guinea pigs designed to identify the molecules responsible for allergen-induced eosinophil accumulation in the lungs (Jose et al. 1994; Rothenberg et al. 1995; Rankin et al. 2000). Subsequently, utilizing genomic analyses, two additional chemokine genes have been identified in the human genome that encode CC chemokines with eosinophil-selective chemoattractant activity, and have hence been designated eotaxin-2 and eotaxin-3 (Zimmermann et al. 2003). Eotaxin-2 and eotaxin-3 are only distantly related to eotaxin-1 since they are only about 30% identical in sequence and are located in a different chromosomal position (Shinkai et al. 1999; Zimmermann et al. 2000b). The specific activity of all eotaxins is mediated by selective expression of the seventransmembrane spanning, G-protein-coupled receptor CCR3, primarily expressed on eosinophils (Murphy 1994; Daugherty et al. 1996; Ponath et al. 1996). Notably, the eotaxin chemokines cooperate with IL-5 in the induction of tissue eosinophilia. IL-5 increases the pool of eotaxin-responsive cells and primes eosinophils to respond to CCR3 ligands (Zimmermann et al. 2003). Furthermore, when given exogenously, eotaxins cooperate with IL-5 to induce substantial production of IL-13 in the lung (Zimmermann et al. 2003). The finding that IL-4 and IL-13 are potent inducers of the eotaxin chemokines by a STAT6-dependent pathway provides an integrated mechanism to explain the eosinophilia associated with Th2 responses (Zimmermann et al. 2003). Recent studies have identified that eosinophil recruitment to the lung is dependent on STAT6 and a bone marrow-derived lung tissue resident non- T or B cell (Voehringer et al. 2004); in particular, eotaxin-2 production by airway macrophages likely accounts for this (Pope et al. 2005a,b). Of further interest, recently CCR3 has been shown to also deliver a powerful negative signal in eosinophils, depending on the ligand engaged. For example, pretreatment with the chemokine Mig inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism (Fulkerson et al. 2005).

Utilizing eotaxin-1 and eotaxin-2 single and double genedeficient mice or neutralizing antibodies, both chemokines have been shown to have nonoverlapping roles in regulating the temporal and regional distribution of eosinophils in an allergic inflammatory site (Rothenberg et al. 1997; Gonzalo et al. 1998; Pope et al. 2005a). Utilizing a standard experimental asthma model induced by systemic sensitization with ovalbumin/alum followed by respiratory ovalbumin challenge, only a modest reduction in lung eosinophils was found in CCR3-deficient mice (Humbles et al. 2002). However, when the same CCR3-deficient mouse line was subjected to experimental asthma induction by epicutaneous ovalbumin sensitization, there was a marked deficiency of lung and BAL eosinophils (Ma et al. 2002). It was proposed that these apparently conflicting results may be related to the sensitization protocol (Ma et al. 2002), but the reason for this apparent discrepancy remains unclear. Notably, another CCR3-deficient mouse strain has recently been shown to have a profound reduction in eosinophil recruitment to the lung in the standard ovalbumin/alum systemic sensitization model (Pope et al. 2005b).

There is now substantial preclinical evidence supporting a role for the eotaxin chemokines in human allergic disease (Zimmermann et al. 2003). Experimental induction of cutaneous and pulmonary late-phase responses in humans has revealed that the eotaxin chemokines are produced by tissue-resident cells (e.g., respiratory epithelial cells and skin fibroblasts) and allergen-induced infiltrative cells (e.g., macrophages and eosinophils). Following allergen challenge in the human lung, eotaxin-1 is induced early (6 hours) and correlates with early eosinophil recruitment; in contrast, eotaxin-2 correlates with eosinophil accumulation at 24 hours (Zimmermann et al. 2003). In another study, eotaxin-1 and eotaxin-2 mRNA were increased in patients with asthma compared with normal controls; however, there was no further increase following allergen challenge (Zimmermann et al. 2003). In contrast, eotaxin-3 mRNA was dramatically enhanced 24 hours after allergen challenge (Zimmermann et al. 2003). The chemoattractant activity of BAL fluid from patients with asthma is inhibited by antibodies against RANTES, MCP-3, MCP-4, and eotaxin-1 (Zimmermann et al. 2003). Further support for an important role of eotaxin-1 in human asthma is derived from analysis of a single nucleotide polymorphism (SNP) in the eotaxin-1 gene. A naturally occurring mutation encoding a change in the last amino acid in the signal peptide (alanine[RIGHTWARDS ARROW]threonine) results in less effective cellular secretion of eotaxin-1 in vitro and in vivo (Nakamura et al. 2001). Notably, this SNP is associated with reduced levels of circulating eotaxin-1 and eosinophils, and improved lung function (e.g., forced expiratory volume in 1 s or FEV1) (Nakamura et al. 2001). Furthermore, an SNP in the eotaxin-3 gene is associated with atopy in a Korean population and eosinophilic esophagitis in a white population (Chae et al. 2005; Blanchard et al. 2006). Recently, the activity of eotaxin-1 and eotaxin-2 in humans has been investigated by injection of these chemokines into the skin of humans; both eotaxin-1 and eotaxin-2 induce an immediate wheal and flare response associated with mast cell degranulation and subsequent infiltrations by eosinophils, basophils, and neutrophils (Menzies-Gow et al. 2002). The infiltration by neutrophils is likely to be mediated indirectly by mast cell degranulation. These results provide substantial evidence that the biological activities attributed to eotaxins in animals are conserved in humans.

ROLE OF EOSINOPHILS IN DISEASE

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils are closely associated with infection by parasitic helminths, as production of Th2 cytokines, specifically IL-5, within cells in infected tissue promotes expansion of progenitor populations in the bone marrow, leading to blood and tissue eosinophilia (Pearce et al. 2004; Wynn et al. 2004; Jankovic et al. 2006). Although in vitro studies suggest that eosinophils can destroy these organisms via secretion of cytotoxic proteins and reactive oxygen species, the results from infection studies carried out in vivo remain unclear and controversial.

Eosinophils are also closely associated with the pathogenesis of allergy, specifically in the respiratory tract, with the development of allergic asthma (Bochner & Busse 2005). Symptomatic wheezing and bronchoconstriction associated with asthma exacerbations can result from a superimposed respiratory virus infection, with common inciting agents including the paramyxovirus pathogen respiratory syncytial virus (hRSV) (Singh et al. 2007). At the same time, primary hRSV infection has intriguing associations with the development of childhood asthma (Everard 2006; Martin et al. 2006; Schaller et al. 2006). In connection with these observations, eosinophil recruitment and degranulation has also been observed in response to primary infection with hRSV, an observation that has been explored in human tissues, in culture systems, and in mouse models.

INFECTION

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Eosinophils and parasitic helminth infection

Profound blood and tissue eosinophilia are among the hallmark features of parasitic helminth infection, observed in response to activation of CD4+ Th2 lymphocytes at specific stages of the parasite life cycle. As noted earlier, although it seems logical to conclude that eosinophils serve as a means of host defense, there are no “errors of nature” (i.e., human conditions or syndromes characterized by a unique eosinophil deficiency) that might provide direct insight into eosinophil function in helminth-related disease. The only eosinophil-specific condition is hereditary EPO deficiency (Romano et al. 1994), which is detected by laboratory analysis and which has not been related to an increased susceptibility to helminth infection in human studies. Interestingly, most of the human data available suggest a role for eosinophils in preventing reinfection (Hagan et al. 1985; Sturrock et al. 1996), a subject that might be addressed further in rodent infection models (Knopf et al. 1977). At the same time, controlled mouse model studies of primary infection have yielded results that are equivocal and, as such, no specific conclusions regarding the role of eosinophils in promoting host defense can be reached. There are several recent reviews that discuss these data in great depth, and provide significant insight into the ongoing controversy (Behm & Ovington 2000; Meeusen & Balic 2000; Klion & Nutman 2004). The primary points are summarized here.

The initial paradigm, that eosinophils might provide host defense against parasitic helminths, came from studies in which activated human eosinophils in the presence of antibody and/or complement, as well as specific eosinophil secretory components alone (e.g., MBP, ECP, EPO), reduced the viability of various helminths in vitro (Butterworth & Franks 1975; Glauert & Butterworth 1977; Hamann et al. 1987). The availability of a monoclonal antibody directed against the eosinophilopoietic cytokine IL-5 permitted studies of the role of eosinophils in host defense against helminth infection to be performed in vivo. Although this reagent resulted in a large-scale reduction in circulating and tissue eosinophilia, there was no evidence for any change in the nature or extent of helminth infection in mouse model studies (Sher et al. 1990a; Herndon & Kayes 1992). Similar conclusions were reached in several studies performed in genetically altered IL-5 transgenic hypereosinophilic mice and in IL-5 and IL-5Rα gene-deleted, eosinophil-deficient mice (Hokibara et al. 1997; Takamoto et al. 1997; Le Goff et al. 2000), as well as more recently in studies performed in the Δdbl-GATA and TgPHIL eosinophil-ablated strains of mice (Swartz et al. 2006). However, among the notable exceptions, eosinophils did appear to play a role in reducing the parasite burden in several studies performed with nematode Strongyloides and Angiostrongylus species. Among these experiments, Korenaga et al. (1991) demonstrated increased recovery of S. venezuelensis worms from lungs of eosinophil-depleted mice treated with anti-IL-5 monoclonal antibody, and Sasaki et al. (1993) and Yoshida et al. (1996) demonstrated prolonged survival and increased recovery of A. cantonensis worms from anti-IL-5-treated and IL-5Rα-deficient mice, respectively. Given the unique tissuemigratory phase of Strongyloides and related nematode species, a role for eosinophils in host defense against specifically tissue-invading helminths has been suggested (Klion & Nutman 2004). A compilation of the reports documenting the results of mouse model studies that have addressed the role of eosinophils in host defense against helminth pathogens is shown in Table 12.3.

Table 12.3.   Eosinophils and host defense against helminth parasites: results from mouse model studies. (Adapted from Klion & Nutman 2004 with permission.
OrganismResults
  1. −, Eosinophils shown to play no role; +, eosinophils shown to provide host defense; ±, conflicting information in the literature.

Cestodes
Mesocestoides corti
Trematode
Fasciola sp.
Schistosoma sp.
Nematodes
Angiostrongylus sp.+
Heligmosomoides polygyrus
Brugia sp.+
Nippostrongylus sp.±
Onchocerca sp.
Strongyloides sp.+
Toxocara sp.
Trichinella sp.±
Trichuris sp.

There are a number of publications that have focused on the role of eosinophils in promoting tissue pathology. A specific role for eosinophils in promoting pathology has been defined in mouse models of corneal inflammation characteristic onchocercal keratitis (Pearlman et al. 1998). However, in other models, such as those exploring the pathogenesis of Schistosoma mansoni and Nippostrongylus brasiliensis infection in eosinophil-deficient mice, the characteristic liver and lung lesions, respectively, are eosinophil depleted, but pathology remains otherwise unchanged (Coffman et al. 1989; Sher et al. 1990b; Swartz et al. 2006) (Fig. 12.8).

image

Figure 128.  Microscopic pathology of hepatic granulomas of Schistosoma mansoni-infected wild-type and eosinophil-ablated Δdbl-GATA and TgPHIL mice. Giemsa-stained liver tissue sections featuring granulomas from S. mansoni-infected BALB/c (a, b), eosinophilablated Δdbl-GATA (c, d), C57BL/6 (e, f), and eosinophil-ablated TgPHIL (g, h) mice, all at 12 weeks of infection. Arrows indicate examples of eosinophils. Original magnifications: × 10 (a, b, e, f); × 40 (c, d, g, h). (From Swartz et al. 2006 with permission.)

Download figure to PowerPoint

There are many reasons why it may be difficult to discern a role for eosinophils in vivo in the mouse experimental system. Among the possibilities, many of these experiments are performed with human pathogens that do not naturally infect rodent species, and thus there is no assurance that one is engaging innate host defense in an evolutionarily meaningful fashion. Related to this point, mouse eosinophils and human eosinophils are not necessarily functionally equivalent (Lee & Lee 2005). While EPO is highly conserved between mouse and human, the eosinophil ribonucleases and MBP are highly divergent. Likewise, mouse and human eosinophils display significant differences in morphology, surface protein expression, and propensity to degranulate in response to physiologic stimuli (Denzler et al. 2001; Clark et al. 2004; Lee & Lee 2005). The inability to observe eosinophils degranulating in response to infectious stimuli in vivo would appear to be a major factor hindering the identification of the role of this cell in host immunity against helminth infection. Different responses observed among various inbred strains of mice likewise add to the overall complexity (Dehlawi & Goyal 2003). Furthermore, it may be simply that we are asking the wrong questions. It remains possible that eosinophils do contribute to host defense, not necessarily by reducing the number of pathogens or eliminating immediate pathologic responses, but instead in a more subtle fashion by contributing to tissue remodeling (De Jesus et al. 2004; Reiman et al. 2006), propensity for reinfection (Knopf et al. 1977; Sturrock et al. 1983), and/or other long-term immunomodulatory sequelae.

Eosinophils and respiratory syncytial virus infection

hRSV is single-stranded negative-sense RNA virus pathogen of the family Paramyxoviridae, subfamily Pneumovirinae that causes respiratory tract infection, primarily among infants and toddlers. The severity of infection can extend from mild upper respiratory symptoms to full-blown bronchiolitis and pneumonia, and may progress to acute respiratory distress syndrome and death, particularly among highly susceptible populations (reviewed in Tripp 2004; DeVincenzo 2005). There is no specific treatment for this infection other than primary support, as neither the antiviral agent ribavirin nor antiinflammatory glucocorticoids have proven impact on the course of disease (Randolph & Wang 1996). A safe and effective human vaccine is not available, although humanized monoclonal antibody directed against the virus fusion (F) protein is approved for treatment of high-risk infants (Cardenas et al. 2005).

Several independent groups have detected eosinophils and/or their degranulation products in BAL washings taken from infants undergoing mechanical ventilation secondary to severe hRSV disease (Garofalo et al. 1992; Harrison et al. 1999; Dimova-Yaneva et al. 2004; Kim et al. 2006). The signals promoting eosinophil recruitment and degranulation have not been defined, although several potential eosinophil chemoattractants, including RANTES and MIP-1α, have been detected in BAL from hRSV-infected infants (Harrison et al. 1999; Garofalo et al. 2001) (Fig. 12.9). Likewise uncertain is the role of eosinophils in primary hRSV infection, as there is no clear evidence from any human studies as to whether they promote host defense or serve to enhance immunopathology. Among these immunopathologies, there is a clear association between severe hRSV infection, particularly among the youngest infants, and the development of postinfection wheezing and asthma (Everard 2006; Martin et al. 2006; Schaller et al. 2006; Singh et al. 2007), the latter related, among other things, to age-dependent Th2 cytokine-mediated recruitment of proinflammatory eosinophils (Zhao et al. 2002; Kristjansson et al. 2005).

image

Figure 129.  Immunoreactive eosinophil granule proteins detected in lower airway secretions. (a) Western blots from lower airway secretions obtained from patients with RSV bronchiolitis (lanes 1–10) or unrelated diagnoses (lanes 11–20) were probed with polyclonal anti-EDN or anti-ECP antisera; C, control: human eosinophil lysate (<1 μg loaded). Detection of (b) ribonuclease activity (units/mL per mg protein) and (c) the proinflammatory chemokine MIP-1α (pg/mL per mg protein) in the same samples. (Adapted from Harrison et al. 1999 with permission.)

Download figure to PowerPoint

Specific observations made in vitro provide potential insight into the role of eosinophils in primary hRSV disease. In correlation with their presence in human BAL washings, hRSVinfected respiratory epithelial cells in culture synthesize both RANTES (CCL5) and MIP-1α (CCL3) (Saito et al. 1997; Harrison et al. 1999; Miller et al. 2004). In support of a role in host defense, Domachowske et al. (1998) have shown that human eosinophils mediate a dose-dependent reduction in hRSV infectivity, an effect directly dependent on degranulation of its unique secretory ribonucleases. Likewise, Adamko et al. (2001) demonstrated that EPO inhibited replication of the related rodent RNA virus pathogen parainfluenza type I in a similar in vitro assay system.

The role of eosinophils in primary infection has also been addressed in the hRSV challenge model in mice. There are some differences between the human and mouse responses to the hRSV pathogen. As hRSV is a human pathogen, it undergoes little or no overt replication in mouse lung tissue and disease does not progress beyond a limited inflammatory state even in response to relatively large viral inocula. It is also important to recognize that most of the information relating to eosinophil recruitment in mice is based on studies of “enhanced disease,” which is an IL-5-mediated allergic response to formalin-fixed virus and virion components (Piedra 2003; Openshaw & Tregoning 2005) and not directly related to primary hRSV infection per se. However, in a recent study, Phipps et al. (2007) demonstrated accelerated clearance of hRSV after primary challenge in IL-5 transgenic hypereosinophilic mice, an effect that is directly dependent on signaling through TLR7. Interestingly, eosinophil recruitment in the primary hRSV challenge model appears to be a function of age, with increasing numbers of eosinophils observed on infection of younger (neonatal) mice (Culley et al. 2002); neonatal challenge is also accompanied by enhanced recruitment of Th2 cells and progression to an allergen-responsive phenotype (You et al. 2006; Barends et al. 2004), similar to what has been observed in hRSV-infected human neonates.

The role of eosinophils in promoting host defense against natural rodent paramyxovirus pathogens has been explored in some detail. In a study directed toward understanding airway hyperresponsiveness, Adamko et al. (1999) identi-fied an eosinophil-dependent reduction in titers of rodent parainfluenza I virus in lungs of mice subjected to ovalbumin sensitization and challenge. Likewise, eosinophil recruitment has been observed as an early response to infection with pneumonia virus of mice (PVM), the cognate rodent pathogen most closely related to hRSV (Domachowske et al. 2000a; Easton et al. 2007). Eosinophil recruitment in response to PVM is not dependent on IL-5, but is blunted (along with recruitment of neutrophils) in mice devoid of the chemokine MIP-1α or its receptor CCR1 (Domachowske et al. 2000b). Preliminary studies suggest that, similar to studies perfomed with hRSV (Phipps et al. 2007), higher titers of virus are detected in lung tissue of the eosinophil-ablated Δdbl-GATA mice (Foster et al. 2007), although protection from the characteristic severe disease state is known to be related to factors other than absolute virus titer (Rosenberg et al. 2005).

In summary, eosinophils are recruited and degranulate in lung tissue in response to hRSV infection. Experiments performed in vitro and in several different mouse models suggest mechanisms underlying eosinophil recruitment, and provide evidence consistent with a role for these cells in promoting virus clearance.

ASTHMA

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Asthma phenotypes

Asthma is a heterogeneous disease with several clinical subtypes and a wide spectrum, ranging from mild, episodic, wheezy breathlessness to chronic, intractable, corticosteroiddependent chronic airway narrowing (Bel 2004). The classical IgE-associated allergic asthma phenotype starting in childhood is the most widely studied, not least because this form of the disease can be provoked in the clinical laboratory under controlled conditions by inhalation of allergen or allergenderived T-cell peptides. In these patients, airway cells have a predominant Th2 cytokine profile (i.e., IL-4+, IL-5+, IL-9+ and IL-13+ mucosal cells). Some asthmatics have late-onset nonallergic (so-called “intrinsic”) asthma in which sensitivity to allergens cannot be identified but in which airway eosinophilia and Th2 cells are also prominent (Humbert et al. 1999). The characteristic features of most asthma phenotypes, including allergic asthma, are airway inflammation, airway hyperresponsiveness (AHR), excessive airway mucus production due to goblet cell hyperplasia, and thickness of the airway wall. This airway thickness, often referred to as remodeling, is consequent to excessive repair processes following repeated airway injury and involves an increase in airway smooth muscle mass, deposition of collagen and other matrix proteins, and new blood vessel formation (Bousquet et al. 1990).

Association with eosinophils

Increases in eosinophils in the tissues, blood, and bone marrow are a hallmark of most asthma phenotypes and, in general, elevated numbers correlate with disease severity (although “noneosinophilic/nonneutrophilic” asthma is characteristic of bacterial, viral, and pollutant triggers) (Douwes et al. 2002). This has led to the hypothesis that the eosinophil is the central effector cell responsible for ongoing airway inflammation. Thus, the cell has the potential to cause damage to the airway mucosa and associated nerves through the release of granule-associated basic proteins (which damage nerves and epithelial cells), lipid mediators (which cause bronchoconstriction and mucus hypersecretion), and reactive oxygen species (which generally injure mucosal cells).

The inflammatory milieu promotes the survival of eosinophils by the elaboration of agents that delay apoptosis. These include epithelial-derived GM-CSF and neurotrophins (e.g., NGF and brain-derived neurotrophic factor) (Hahn et al. 2006). Eosinophils are also highly sensitive to Fas-mediated apoptosis. In a mouse model of asthma, Fas-positive T cells were found to regulate the resolution of airway inflammation since Fas deficiency on T cells produced long-term allergic airways disease (Tong et al. 2006).

Blood eosinophils from patients with asthma have a number of phenotypic alterations, particularly in relation to their adhesive properties. Thus airway eosinophils recovered after antigen challenge have enhanced adhesion to VCAM-1 (CD106) and other ligands including albumin, ICAM-1 (CD54), fibrinogen, and vitronectin. These hyperadhesive properties seem to be mediated by upregulated and activated αMβ2 (CD11b/18) (Barthel et al. 2006). Asthmatic eosinophils also have increased expression of collagen receptors α1β1 and α2β1 integrins (Bazan-Socha et al. 2006).

More attention is now given to a possible role for the eosinophil in repair and remodeling processes since there is a well-documented association of tissue eosinophilia and eosinophil degranulation with certain fibrotic syndromes and the cell is the source of several fibrogenic and growth factors, including TGF-α, TGF-β, fibroblast growth factor (FGF)-2, vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-9, IL-1β, IL-13, and IL-17 (see Fig. 12.6).

Eosinophils and animal models of asthma

Over the years animal models of asthma have often given conflicting results, especially those involving short-term sensitization (models of repeat allergen inhalation appear to be more reproducible). For example, two groups used experimental models of airway inflammation in mice genetargeted for complete and selective ablation of the eosinophil lineage. In one model eosinophils were targeted through transgenic expression of the diphtheria toxin A chain under control of the eosinophil peroxidase promoter (PHIL) (Lee et al. 2004). The authors of the study concluded that eosinophils were required for both AHR and mucus accumulation. Other workers have ablated the eosinophil lineage by deleting the high-affinity GATA-1 binding site on the palindromic GATA-1 promoter (Δdbl) but found that these same features of experimental asthma were unaffected by eosinophil depletion, although the cell did appear to play a critical role in airway remodeling (Humbles et al. 2004). Such anomalies have previously been explained by differences in the strains of animals used (Shinagawa & Kojima 2003) and different experimental protocols.

Animal studies have demonstrated a role for eosinophils in airway remodeling. The Δdbl-GATA animals were clearly protected from peribronchiolar collagen deposition and increases in airway smooth muscle (Humbles et al. 2004). Furthermore, in a chronic repetitive allergen challenge model, Cho et al. (2004) found that IL-5 gene deletion suppressed lung eosinophilia, peribronchial fibrosis, collagen III, collagen V and total lung collagen content in parallel. These changes were associated with decreased TGF-α1 content of lung tissue, with evidence that eosinophils were the major source. Interestingly, epithelial cell expression of αvβ6, an integrin that activates latent TGF-β1, was also suppressed. Peribronchial smooth muscle thickness and epithelial mucus expression were also reduced. Others have observed reduced airway eosinophilia, TGF-β production, and remodeling in IL-5 knockout animals, and increased airway fibrosis in IL-5 transgenic animals after repeated allergen inhalation (Tanaka et al. 2004). It was surprising therefore that the reduced subepithelial cell fibrosis observed in the Δdbl-GATA line were apparently independent of TGF-β expression. However there are other potential fibrogenic pathway activators as shown diagrammatically in Fig. 12.10.

image

Figure 1210.  Pathways to wheezy breathlessness in asthma. Airway narrowing, the cause of wheezy breathlessness, can result from several mechanisms, many of which overlap. Early and late reactions are clinical models. The early asthmatic reaction can be largely blocked by antihistamines and anti-cysteinyl leukotrienes and is largely mast cell/IgE-mediated. The late asthmatic reaction is partially dependent on the early response and is “blunted” by leukotriene receptor antagonists. The late-phase reaction also has a T-cell component and may involve antigen trapping and focusing by IgE-bound dendritic cells prior to presentation to, and activation of, Th2 cells. In airway hyperresponsiveness (AHR), nonspecific triggers such as smoke, dust, and fumes induce wheezing on a background of airway inflammation. The mechanisms underlying AHR include enhanced neural pathways, alterations in airway smooth muscle (ASM), and T cell- and mast cell-dependent pathways. Airway remodeling probably has a major eosinophil component as shown in both animals and human. Eosinophils are also prominent in natural exacerbations of the disease triggered by viral and nonviral agents. DC, dendritic cell; Th, T helper cell.

Download figure to PowerPoint

Remodeling in clinical asthma

The precise clinical significance of airway remodeling is debated. One view is that the thickness of the wall, the overall consequence of remodeling, leads to a decrease in baseline caliber (i.e., the radius of the airway lumen), resulting in a disproportionate increase in airway resistance, which in turn enhances AHR. Others point out that corticosteroids, the mainstay antiinflammatory treatment in the disease, reverse some but not all the features of remodeling. Nevertheless there is a hard core of asthmatics who are steroid resistant and airway remodeling is often quite marked in asthma deaths.

Studies in humans using anti-IL-5 antibodies also support a role for eosinophils in events surrounding deposition of certain matrix proteins within the reticular basement membrane (Kay et al. 2004). IL-5 is a key cytokine in eosinophil differentiation, maturation, recruitment, and activation at sites of inflammation. It stimulates the expansion and differentiation of eosinophil precursors and upregulates expression of its own specific receptor α chain during human eosinophil development. Anti-IL-5 has a good safety profile and anxieties regarding increased susceptibility to helminths and tumors appear, so far, unfounded. When asthmatics were given three infusions of anti-IL-5 (mepolizumab) this produced about a 90% reduction in blood and bronchial lavage eosinophils but only 55% reduction in bronchial mucosal eosinophils (Flood-Page et al. 2003b). However, even this modest effect produced significant reduction in tenascin, lumican, and procollagen III compared with placebo (Flood-Page et al. 2003c). There was also a significant reduction in the numbers and percentage of tissue eosinophils expressing mRNA for TGF-β1 as well as the concentration of TGF-β1 in BAL fluid. Although there were no appreciable improvements in clinical outcomes, the study was not powered to detect changes in lung function or AHR. Nevertheless, the results do provide strong evidence that there is a causal relation between eosinophils and matrix deposition in the extracellular matrix. The clinical significance of these findings is unclear, especially as fibroblast accumulation and airway smooth muscle cell hypertrophy in proximal airways seem to be more selective determinants of severe persistent asthma than matrix deposition beneath the basement membrane (Benayoun et al. 2003).

A further complicating factor is the role of atopy. For example, airway eosinophilia and angiogenesis were observed in bronchial biopsies from atopic children without asthma (Barbato et al. 2006) and eosinophilic inflammation and increased AHR have been observed in adult patients with allergic rhinitis (Tatar et al. 2005). On the other hand, intense bronchial mucosal eosinophilia is a feature of nonatopic (“intrinsic”) asthma. One interpretation of these findings is that eosinophil-mediated damage precedes the development of overt asthma irrespective of the atopic status.

In order to provide definitive evidence that eosinophils are key cells in airway remodeling, more effective strategies are required to deplete tissue eosinophils. Even in animal models of asthma there was residual tissue eosinophilia in the airways after anti-IL-5 administration (Foster et al. 2001). In fact depletion of both IL-5 and eotaxin are required to abolish tissue eosinophils and AHR in mice, suggesting that IL-5 blockade alone is insufficient. Combination therapy with, for example, anti-IL-5 and a CCR3 antagonist may be more useful than IL-5 blockade alone, since this would have the theoretical advantage of inhibiting both bone marrow maturation (mainly an IL-5 effect) and tissue accumulation (predominantly a CCR3-dependent effect). In a mouse model, ablation of eotaxin chemokines prevented antigeninduced pulmonary eosinophilia (Pope et al. 2005b) and antagonism of CCR3 reduced eosinophil numbers and this was accompanied by a diminution in asthma pathology (Weigmann et al. 2007).

Eosinophils are also known to localize to cholinergic nerves in a variety of inflammatory conditions including asthma. This effect appears to be the result of enhanced eotaxin production by neurons, possibly as a result of IL-4 and IL-13 upregulation (Fryer et al. 2006). These events result in damage of inhibitory M2 receptors by eosinophil MBP (Evans et al. 1997) and reduced catabolism of acetylcholine (Durcan et al. 2006).

Eosinophils and the late asthmatic reaction

When clinical asthma is provoked experimentally by inhalation of allergen, there are two general patterns of airway narrowing, termed the early asthmatic reaction (EAR) and late asthmatic reaction (LAR). The EAR (as measured by changes in FEV1 as a test of airway narrowing) peaks within 15–30 min after allergen challenge and returns nearly to baseline by 1 hour. In this sense it is a “bronchospastic” reaction and involves the IgE-dependent release from mast cells of histamine and other mediators, including leukotrienes, prostaglandins, and tryptase. The LAR, on the other hand, is characterized by a delayed course and slow decrease in FEV1 (which peaks between 3 and 9 hours), and tends to resolve by 24 hours. The mechanism(s) of the LAR is controversial, although there is good evidence to suggest that there is a significant T-cell component because isolated LAR (i.e., without the EAR component) can be provoked by inhalation of allergen-derived T-cell peptides (which do not cross-link IgE and cause mast cell activation) (Haselden et al. 1999). Furthermore, the immunosuppressant cyclosporin A blocks the late, but not the early, asthmatic reaction (Sihra et al. 1997). Thus the LAR may involve direct interaction between activated T cells (presumed Th2 cells) and airway smooth muscle subsequent to IgE-dependent trapping and focusing by airway dendritic cells.

The role of the eosinophil in the LAR and in AHR remains uncertain. The original observation of Cockcroft et al. (1977) was that allergen inhalation increased AHR in dual asthmatic responders which was sustained for at least 7 days. The temporal association between increased inflammatory cell infiltration and increased AHR at 24 hours after allergen challenge in dual responders (Brusasco et al. 1990; Flood-Page et al. 2003b; Dorman et al. 2004a) has led to the suggestion of a causal relationship between the two. However, Kariyawasam et al. (2007) showed that allergen-induced increases in eosinophilic airway inflammation, while marked at 24 hours in dual asthmatic responders, were virtually resolved by 7 days. On the other hand, increases in AHR and expression of collagen markers of airway remodeling persisted. Other less direct evidence also supports the view that cellular inflammation, particularly eosinophil infiltration (Dorman et al. 2004b), does not necessarily directly relate to AHR (Djukanovic et al. 1990; Ollerenshaw & Woolcock 1992; Iredale et al. 1994; Crimi et al. 1998; Dorman et al. 2004b).

In an allergen-induced study by Gauvreau et al. (1999) on the cellular kinetics of cells in induced sputum, eosinophilia remained elevated 7 days after allergen inhalation challenge, albeit at levels considerably less than at 24 hours. This is in contrast to the finding of others who observed resolution of mucosal eosinophils to baseline levels by this time point (Kariyawasam et al. 2007). The reason for this difference between measures of airway luminal eosinophils and tissue cells is not clear but may reflect eosinophils that have been cleared from the submucosa but can still be detected in the sputum at a time point when tissue infiltration has resolved.

Attempts to deplete eosinophils selectively in humans have been largely unsuccessful and as such we have been unable to fully resolve the role of this cell in the asthma process. The first study in humans showed that a single infusion of anti-IL-5 produced a significant reduction in both blood and induced sputum eosinophils, but no appreciable changes in either the LAR or AHR (Leckie et al. 2000). However, a subsequent study (Flood-Page et al. 2003c) involving three infusions indicated that mepolizumab was unable to deplete tissue eosinophils, i.e., from the bronchial mucosa, making interpretation of the single infusion study problematic (O'Byrne et al. 2001; Flood-Page et al. 2002, 2003b; Leckie 2003). Nevertheless, further evidence against a role for eosinophils as causative of the late reaction comes from studies in human skin in which it has been shown that the kinetics of eosinophil accumulation can be dissociated from the time course of the late-phase allergic reaction and that profound reduction of eosinophils (again by anti-IL-5) do not affect the magnitude of the allergen-induced cutaneous swelling and edema (Phipps et al. 2004a).

Eosinophils and airway hyperresponsiveness

There is no firm evidence that eosinophils or their products are directly causative in AHR in clinical asthma. The correlation between blood and tissue eosinophils and the degree of AHR is generally weak or nonexistent. Following a single infusion of anti-IL-5 there was no change in AHR, even when patients were followed up for several weeks, although this study may have been flawed for the reasons already stated above (Leckie et al. 2000). Further evidence casting doubt on a role for eosinophils in AHR comes from studies of eosinophilic bronchitis (Brightling et al. 2002, 2003). In this condition there is a similar distribution of eosinophils in the airways to that found in asthma, although there is no wheezy breathlessness or AHR (Brightling et al. 2003). The only histopathologic feature distinguishing asthma from eosinophilic bronchitis was mast cells associated with airway smooth muscle cells.

Eosinophils and natural exacerbations of asthma

Severe persistent asthma is characterized by viral- and nonviral-induced natural exacerbations on a background of chronic inflammation. An increase in blood or sputum eosinophils often predates deterioration in symptoms and lung function. In fact a management strategy directed at normalizing the sputum eosinophil count was more effective than traditional management strategy (based on lung function, assessment of symptoms, and use of rescue β2 agonists) in reducing the number of asthma exacerbations (Green et al. 2002). It is interesting to speculate that eosinophil-derived fibrogenic/growth factors amplify airway remodeling and associated mucus production relatively rapidly and that this in turn leads to deterioration in symptoms. In a recent study it was shown that even a single allergen inhalation could induce acute airway remodeling in mild atopic asthmatics (Phipps et al. 2004b). Endobronchial mucosal biopsies obtained 24 hours after challenge showed significant increases in Hsp47, a chaperone of collagen synthesis as well as STAT6 and phospho-Smad2 as evidence of IL-4/IL-13 and TGF-β activated cells respectively. There were also increases in the thickness of tenascin within the reticular basement membrane. Therefore (“eosinophilic”) airway remodeling in asthma may partly result from repeated acute activation of the epithelial mesenchymal trophic unit by allergen exposure.

Conclusions

There are many areas of remodeling that require further investigation. The precise relationship between chronic inflammation and remodeling is still unclear. Some studies suggest that remodeling might even predate the first signs of inflammation and be an independent event that is amplified rather than caused by Th2 inflammation. The genetic predisposition to airway remodeling, including gene expression by resident cells from normal and diseased airways, is an important area for future research as is the precise effects of the various components of remodeling on airway function. For example, the consequence of subepithial fibrosis to chronic airway obstruction is still unknown and the importance of angiogenesis, one of the few components of remodeling reversed by corticosteroids, in inflammation and edema is poorly understood.

Animal and human studies point to an important function of eosinophils in airway remodeling in asthma. The cell probably also plays a critical role in natural exacerbations of the disease. The significance of eosinophils in the LAR and in AHR, at least in the clinical situation, is far less certain. Studies on the role of the cell in AHR and mucus production, using eosinophil-lineage depletion in mice, has given diametrically opposite results, emphasizing the difficulties of animal models in mimicking the natural disease in humans.

Eosinophil-associated gastrointestinal diseases

Eosinophil accumulation in the gastrointestinal tract is a common feature of numerous gastrointestinal disorders, including classic IgE-mediated food allergy (Saavedra-Delgado & Metcalfe 1985; Moon & Kleinman 1995), eosinophilic gastroenteritis (Keshavarzian et al. 1985; Torpier et al. 1988), allergic colitis (Sherman & Cox 1982; Hill & Milla 1990; Odze et al. 1995), eosinophilic esophagitis (Furuta 1998; Rothenberg et al. 2001b; Fox et al. 2002), inflammatory bowel disease (IBD) (Sarin et al. 1978; Dvorak 1980; Walsh & Gaginella 1991), and gastroesophageal reflux disease (Winter et al. 1982; Brown et al. 1984; Liacouras et al. 1998). In IBD, eosinophils usually represent only a small percentage of the infiltrating leukocytes (Walsh & Gaginella 1991; Desreumaux et al. 1999), but their level has been proposed to be a negative prognostic indicator (Nishitani et al. 1998; Desreumaux et al. 1999). Primary eosinophil-associated gastrointestinal diseases (EGIDs) such as eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic enteritis, and eosinophilic colitis are defined as disorders that primarily affect the gastrointestinal tract with eosinophil-rich inflammation in the absence of known causes of eosinophilia (e.g., drug reactions, parasitic infections, malignancy). Patients with EGIDs suffer a variety of problems, including failure to thrive, abdominal pain, irritability, gastric dysmotility, vomiting, diarrhea, and dysphagia (Guajardo et al. 2002; Khan & Orenstein 2002). Evidence is accumulating to support the concept that EGIDs arise secondary to the interplay of genetic and environmental factors. Notably, a large percentage (∼10%) of patients suffering from EGID have an immediate family member with EGID (Guajardo et al. 2002). Additionally, several lines of evidence support an allergic etiology: (i) about 75% of patients with EGID are atopic (Caldwell et al. 1975; Cello 1979; Scudamore et al. 1982; Furuta et al. 1995; Iacono et al. 1996; Sampson 1997; Walsh et al. 1999; Spergel et al. 2002); (ii) the severity of disease can sometimes be reversed by institution of an allergen-free diet (Kelly et al. 1995; Walsh et al. 1999; Spergel et al. 2002); and (iii) the common finding of mast cell degranulation in tissue specimens (Oyaizu et al. 1985; Bischoff 1996). Importantly, our recent models of EGID support a potential allergic etiology for these disorders (Rothenberg et al. 2001c). Interestingly, despite the common finding of food-specific IgE in patients with EGID, foodinduced anaphylactic responses only occur in a minority of patients (Sampson 1999). Thus, EGIDs have properties that fall between pure IgE-mediated food allergy and cell-mediated hypersensitivity disorders (e.g., celiac disease) (Sampson 1999).

Hypereosinophilic syndromes

The term “hypereosinophilic syndrome” (HES) was introduced by Anderson and Hardy (1968) to designate patients with marked eosinophilia. They reported three patients, all males, between the ages of 34 and 47 who suffered from cardiopulmonary symptoms, fever, sweats, weight loss, and marked eosinophilia. Two of the patients died, and at autopsy their hearts were enlarged and showed mural thrombi. The treatment for HES is similar to that used for patients with chronic myelogenous leukemia, including prednisone, hydroxyurea (hydroxycarbamide), and interferon (IFN)-α. Chusid et al. (1975) formulated the diagnostic criteria for HES to include (i) persistent eosinophilia, with an eosinophil cell count of at least 1.5 × 109/L for a minimum of 6 months; (ii) lack of known causes for eosinophilia (e.g., parasitic or allergic triggers); and (iii) symptoms and signs of organ system involvement. Based on these diagnostic criteria, patients with EGID and blood eosinophil counts in excess of 1.5 × 109/L meet the diagnostic criteria. However, patients with EGID generally do not have the high risk of life-threatening complications associated with classic HES (i.e., cardiomyopathy or central nervous system involvement). Notably, considerable heterogeneity among patients with HES has been recognized. For example, T-cell clones producing the characteristic Th2 cytokines IL-4 and IL-5 have been found in patients satisfying the diagnostic criteria for HES (Simon et al. 1999; Roufosse et al. 2003).

However, perhaps the most striking advance in our understanding of HES has come about following treatment of HES patients with the tyrosine kinase inhibitor imatinib mesylate (Schaller & Burkland 2001; Ault et al. 2002; Gleich et al. 2002; Cools et al. 2003; Cortes et al. 2003). Imatinib was introduced for the treatment of chronic myelogenous leukemia and has had a remarkable effect in that disease. Treatment of many HES patients with imatinib mesylate causes a dramatic reduction of peripheral blood and bone marrow eosinophils, suggesting that certain HES patients express a novel kinase sensitive to imatinib mesylate. Further investigation of the ability of imatinib mesylate to treat HES patients revealed the existence of an 800-kb deletion in chromosome 4 bringing together an upstream DNA sequence homologous to a yeast protein, referred to as FIP1, and designated as like FIP1 or FIP1-L1, and the gene for the cytoplasmic domain of the platelet-derived growth factor α (PDGFRA) receptor (Cools et al. 2003; Griffin et al. 2003). This fusion gene is transcribed and translated to yield a novel kinase referred to as FIP-L1-PDGFRA; FIP-L1-PDGFRA is exquisitely sensitive to imatinib in vitro, thus explaining the remarkable sensitivity of HES patients to this drug. The FIP-L1-PDGFRA fusion gene cooperates with IL-5 overexpression in a murine model of HES, suggesting that both pathogenic events cooperate in disease etiology (Yamada et al. 2006).

The patients responsive to imatinib are those most characteristic of “classic” HES, namely males between the ages of 20 and 50 who present clinically with marked peripheral blood eosinophilia. Recently, these patients have been shown to meet minor criteria for systemic mastocytosis, having elevated levels of serum mast cell tryptase and high numbers of dysplastic mast cells in the bone marrow (Klion et al. 2003, 2004a). These patients go on to develop eosinophilic endomyocardial disease with embolization to peripheral organs including the extremities and the brain, and they strikingly resemble the patients originally designated by Hardy and Anderson. However, it appears that any disease that results in prolonged and marked eosinophilia can be associated with endomyocardial disease. For example, endomyocardial disease has occurred during the course of helminth infections and also in various malignancies associated with marked eosinophilia (Hussain et al. 1994; Yoshida et al. 1995; Andy et al. 1998). Thus patients with marked eosinophilia are at risk of developing cardiac disease regardless of the underlying etiology of the eosinophilia. Accordingly, routine surveillance of the cardiorespiratory system (e.g., echocardiography and plethysmography) in patients with EGID and peripheral blood eosinophilia is warranted. Based on these concerns, the diagnosis of HES in patients with EGID should always be considered, especially in those who develop extragastrointestinal manifestations (e.g., splenomegaly, or cutaneous, cardiac or respiratory systems). As such, additional diagnostic testing for HES should be considered including bone marrow analysis (searching for evidence of myelodysplasia), serum mast cell tryptase and vitamin B12 levels (both moderately elevated in classic HES), and genetic analysis for the presence of the FIP1-L1-PDGFRA fusion event (Klion et al. 2003).

ANTI-EOSINOPHIL THERAPEUTICS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Numerous drugs inhibit eosinophil production or eosinophilderived products, including glucocorticoids, myelosuppressive drugs, leukotriene synthesis or receptor antagonists, tyrosine kinase inhibitors, IFN-α, and humanized anti-IL-5 antibodies. The etiology of the primary disease often specifies the best therapeutic strategy. For example, a subset of patients with HES have an 800-kb interstitial deletion on chromosome 4 (4q12) that results in the fusion of an unknown gene FIP1-L1 with PDGFRA (Cools et al. 2003, 2004a,b). This fusion gene produces a constitutively active tyrosine kinase (PDGFRA) that is exquisitively sensitive to the inhibitor imatinib mesylate, which is now approved for the treatment of HES (Gleevec). Although PDGFRA is not normally active in hematopoietic cells, the activated kinase renders cells growth factor independent, perhaps by activating STAT5 signal transduction. Thus, eosinophilic patients with FIP1-L1-PDGFRA-positive disease are now treated with Gleevec as first-line therapy (Gleich et al. 2002). In addition, a variety of other activated tyrosine kinases have just been associated with HES, including PDGFR-β, Janus kinase-2, and FGF receptor 1.

In most other individuals, glucocorticoids are the most effective agents for reducing eosinophilia (Rothenberg 1998). They suppress the transcription of a number of genes for inflammatory mediators, including the genes for IL-3, IL-4, IL-5, GM-CSF, and various chemokines including the eotaxins. Recently, the main action of glucocorticoids on eosinophil active cytokines has been shown to involve mRNA destabilization, thus reducing the half-life of cytokines such as eotaxins (Stellato et al. 1999). In addition, glucocorticoids inhibit the cytokine-dependent survival of eosinophils (Schleimer & Bochner 1994). Systemic or topical (inhaled or intranasal) glucocorticoid treatment typically causes a rapid reduction in eosinophils, but a few patients are glucocorticoid resistant and maintain eosinophilia despite high doses (Barnes & Adcock 1995). The mechanism of glucocorticoid resistance is unclear, but a reduced level of glucocorticoid receptors and alterations in transcription factor AP-1 (activator protein 1) appear to be at least partially responsible in some of them (Barnes & Adcock 1995).

Glucocorticoid-resistant patients sometimes require other therapy such as myelosuppressive drugs (hydroxyurea, vincristine) or IFN-α (Rothenberg 1998). IFN-α can be especially helpful because it inhibits eosinophil degranulation and effector function (Aldebert et al. 1996). Notably, patients with myeloproliferative variants of HES can often go into remission with IFN-α therapy. Cyclophilins (e.g., cyclosporin A) have also been used because they block the transcription of numerous eosinophil-active cytokines (e.g., IL-5, GM-CSF) (Rothenberg 1998). Recently, lidocaine has been shown to shorten eosinophil survival, and its effects mimic those of glucocorticoids and are noncytotoxic (Bankers-Fulbright et al. 1998). Indeed, an early clinical trial has shown that nebulized lidocaine is safe and effective in subjects with asthma (Hunt et al. 2004).

Drugs that interfere with eosinophil chemotactic signals include recently approved leukotriene antagonists and inhibitors. Inhibition of 5-lipoxygenase (e.g., zileuton) blocks the rate-limiting step in leukotriene synthesis and inhibits the generation of the eosinophil chemoattractant LTB4 and the cysteinyl leukotrienes (Kane et al. 1996). Cysteinyl leukotriene receptor antagonists block the muscle contraction and increased vascular permeability mediated by leukocyte-derived leukotrienes (Gaddy et al. 1992). Some of the third-generation antihistamines inhibit the vacuolization (Snyman et al. 1992) and accumulation (Redier et al. 1992) of eosinophils after allergen challenge and directly inhibit eosinophils in vitro (Rand et al. 1988; Snyman et al. 1992). Cromoglycate and nedocromil inhibit the effector function of eosinophils such as antibody-dependent cellular cytotoxicity (Rand et al. 1988).

The identification of molecules that specifically regulate eosinophil function and/or production offers new therapeutic strategies in the pipeline. Agents that interrupt eosinophil adhesion to the endothelium through the interaction of CD18/ICAM-1 (Wegner et al. 1990) or VLA-4/VCAM-1 may be useful (Kuijpers et al. 1993; Weg et al. 1993). Indeed, antibodies that block these pathways have recently been approved for other indications, but their anti-eosinophil activity has yet to be determined (von Andrian & Engelhardt 2003). Antibodies against IL-5, now humanized by two different pharmaceutical companies, are under active clinical investigation (Egan et al. 1995; Mauser et al. 1995) and look particularly promising for the treatment of HES (Garrett et al. 2004; Klion et al. 2004b, 2006) and eosinophilic esophagitis (Stein et al. 2006). While its utility for asthma may be limited due to redundant pathways, anti-IL-5 is particularly promising for HES. Numerous inhibitors of the eotaxin/CCR3 pathway, including small-molecule inhibitors of CCR3 and a human anti-eotaxin-1 antibody, are being developed (Zimmermann et al. 2003). Early results with a phase I trial of human antieotaxin-1 antibody in patients with allergic rhinitis have demonstrated the ability of this apparently safe drug to lower levels of eosinophils in nasal washes and nasal biopsies, and to improve nasal patency (Zimmermann et al. 2003). Antihuman IL-13 antibody is now in early clinical trials (Blanchard et al. 2005) and looks promising for lowering tissue eosinophil levels and improving features of asthma. Finally, a recently identified eosinophil surface molecule, Siglec-8, may offer a therapeutic opportunity (Nutku et al. 2003). Siglec-8 is a member of the sialic acid-binding lectin family and contains ITIMs (immunoreceptor tyrosine-based inhibitory motifs) that can induce efficient eosinophil apoptosis when engaged by anti-Siglec-8 cross-linking antibodies. It is interesting to note that Siglec-8, as well as CCR-3 and CRTH2, are coexpressed by other cells involved in Th2 responses including Th2 cells, mast cells, and basophils. Thus, agents that block these receptors may be particularly useful for allergic disorders.

CONCLUSIONS

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES

Historically, eosinophils have been considered end-stage cells involved in host protection against parasites. However, numerous lines of evidence have now changed this perspective by showing that eosinophils are pleiotropic multifunctional leukocytes involved in initiation and propagation of diverse inflammatory responses, as well as modulators of adaptive immunity by directly activating T cells. As normal constituents of the mucosal immune system, particularly in the gastrointestinal tract, eosinophils are likely to have a physiologic function. Indeed, eosinophils have been implicated in innate immunity by being an early and possibly instrumental source of cytokines (e.g., IL-4) and have been shown to have a role in developmental processes such as mammary gland development. Analysis of recently generated genetically engineered eosinophil-deficient mice will soon answer critical questions concerning the true involvement of this cell type in a variety of processes. Breakthroughs in identifying key eosinophil regulatory cytokines such as IL-5 and the eotaxin subfamily of chemokines have uncovered mechanisms that selectively regulate eosinophil production and localization at baseline and during inflammatory responses. In particular, an integrated mechanism involving Th2 cell-derived IL-5 regulating eosinophil expansion in the bone marrow and blood and Th2 cell-derived IL-13 regulating eotaxin production now explains the means by which T cells regulate eosinophils. Based on these findings, it is predicted that targeted therapy against key eosinophil regulators (e.g., humanized anti-IL-5 and CCR3 antagonists) will likely transform medical management of eosinophilic patients.

REFERENCES

  1. Top of page
  2. SUMMARY
  3. INTRODUCTION
  4. EOSINOPHIL GRANULE PROTEINS
  5. MAJOR BASIC PROTEIN
  6. EOSINOPHIL CATIONIC PROTEIN
  7. EOSINOPHIL-DERIVED NEUROTOXIN
  8. EOSINOPHIL PEROXIDASE
  9. CYTOKINES
  10. OTHER EOSINOPHIL-DERIVED MEDIATORS
  11. EOSINOPHILS EXPRESS SNARE ISOFORMS
  12. EOSINOPHIL SURFACE MARKERS
  13. EOSINOPHILS AND IMMUNE REGULATION
  14. EOSINOPHIL DEVELOPMENT
  15. EOSINOPHIL TRAFFICKING
  16. ROLE OF EOSINOPHILS IN DISEASE
  17. INFECTION
  18. ASTHMA
  19. ANTI-EOSINOPHIL THERAPEUTICS
  20. CONCLUSIONS
  21. REFERENCES
  • Abraham W.M., Sielczak M.W., Ahmed A. et al. (1994) Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 93:77687.
  • Abu Ghazaleh R., Fujisawa T., Mestecky J., Kyle R.A., & Gleich G.J. (1989) IgA-induced eosinophil degranulation. J Immunol 142:2393400.
  • Ackerman S.J., Kephart G.M., Habermann T.M., Greipp P.R., & Gleich G.J. (1983) Localization of eosinophil granule major basic protein in human basophils. J Exp Med 158:94661.
  • Ackerman S.J., Gleich G.J., Loegering D.A., Richardson B.A., & Butterworth A.E. (1985) Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. Am J Trop Med Hyg 34:73545.
  • Ackerman S.J., Liu L., Kwatia M.A. et al. (2002) Charcot–Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem 277:1485968.
  • Adamko D.J., Yost B.L., Gleich G.J., Fryer A.D., & Jacoby D.B. (1999) Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection: eosinophils mediate airway hyperresponsiveness, M2 muscarinic receptor dysfunction and antiviral effects. J Exp Med 1999:146577.
  • Adamko D.J., Yost B.L., Gleich G.J., Fryer A.D., & Jacoby D.B. (2001) Antiviral activity of eosinophil peroxidase mediated via sodium bromide. Abstract 018, International Meeting of the Eosinophil Society, May 3–6, 2001, Banff, Alberta, Canada.
  • Advani R.J., Yang B., Prekeris R., Lee K.C., Klumperman J., & Scheller R.H. (1999) VAMP-7 mediates vesicular transport from endosomes to lysosomes. J Cell Biol 146:76576.
  • Aldebert D., Lamkhioued B., Desaint C. et al. (1996) Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood 87:235460.
  • Anderson R.E., & Hardy W.R. (1968) Hypereosinophilia. Ann Intern Med 69:13312.
  • Andy J.J., Ogunowo P.O., Akpan N.A., Odigwe C.O., Ekanem I.A., & Esin R.A. (1998) Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 69:12740.
  • Ault P., Cortes J., Koller C., Kaled E.S., & Kantarjian H. (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:8814.
  • Bandeira-Melo C., Bozza P.T., Diaz B.L. et al. (2000) Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergeninduced eosinophil trafficking. J Immunol 164:226771.
  • Bandeira-Melo C., Woods L.J., Phoofolo M., & Weller P.F. (2002a) Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 196:84150.
  • Bandeira-Melo C., Hall J.C., Penrose J.F., & Weller P.F. (2002b) Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin Immunol 109:9759.
  • Bankers-Fulbright J.L., Kephart G.M., Loegering D.A. et al. (1998) Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. J Immunol 160:554653.
  • Barbato A., Turato G., Baraldo S. et al. (2006) Epithelial damages and angiogenesis in the airways of children with asthma. Am J Respir Cell Mol Biol 35:37886.
  • Barends M., De Rond L.G., Dormans J. et al. (2004) Respiratory syncytial virus, pneumonia virus of mice, and influenza A virus differently affect respiratory allergy in mice. Clin Exp Allergy 34:48896.
  • Barker R.L., Gleich G.J., & Pease L.R. (1988) Acidic precursor revealed in human eosinophil granule major basic protein cDNA. J Exp Med 168:14938 [Erratum appears in J Exp Med (1989) 170, 1057.].
  • Barker R.L., Loegering D.A., Ten R.M., Hamann K.J., Pease L.R., & Gleich G.J. (1989) Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. J Immunol 143:9525.
  • Barnes P.J., & Adcock I.M. (1995) Steroid resistance in asthma. Q J Med 88:45568.
  • Barthel S.R., Jarjour N.N., Mosher D.F., & Johnansson M.W. (2006) Dissection of the hyperadhesive phenotype of airway eosinophils in asthma. Am J Respir Cell Mol Biol 35:37886.
  • Bazan-Socha S., Bukiej A., Pulka G., Marcinkiewicz C., & Musial J. (2006) Increased expression of collagen receptors: a1b1 and a2b1 integrins on blood eosinophils in bronchial asthma. Clin Exp Allergy 36:118491.
  • Behm C.A., & Ovington K.S. (2000) The role of eosinophils in parasitic helminth infections: insights from genetically modified mice. Parasitol Today 16:2029.
  • Bel E.H. (2004) Clinical phenotypes of asthma. Curr Opin Pulm Med 10:4450.
  • Benayoun L., Druilhe A., Dombret M.C., Aubier M., & Pretolani M. (2003) Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 167:13608.
  • Berg E.L., McEvoy L.M., Berlin C., Bargatze R.F., & Butcher E.C. (1993) L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 366:6958.
  • Bischoff S.C. (1996) Mucosal allergy: role of mast cells and eosinophil granulocytes in the gut. Baillieres Clin Gastroenterol 10:44359.
  • Blanchard C., Mishra A., Saito-Akei H., Monk P., Anderson I., & Rothenberg M.E. (2005) Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by antihuman-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35:1096103.
  • Blanchard C., Wang N., Stringer K.F. et al. (2006) Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116:53647.
  • Bochner B.S., & Busse W.W. (2005) Allergy and asthma. J Allergy Clin Immunol 115:9539.
  • Bochner B.S., & Schleimer R.P. (1994) The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol 94:42738.
  • Bochner B.S., & Schleimer R.P. (2001) Mast cells, basophils and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 179:515.
  • Bousquet J., Jeffery P., Busse W., Johnson M., & Vignola A. (1990) Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161:172045.
  • Boyce J.A., Friend D., Matsumoto R., Austen K.F., & Owen W.F. (1995) Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med 182:4957.
  • Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., & Pavord I.D. (2002) Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:1699705.
  • Brightling C.E., Symon F.A., Birring S.S., Bradding P., Wardlaw A.J., & Pavord I.D. (2003) Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 58:52832.
  • Brottman G.M., Regelmann W.E., Slungaard A., & Wangensteen O.D. (1996) Effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatr Pulmonol 21:15966.
  • Brown L.F., Goldman H., & Antonioli D.A. (1984) Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis. Am J Surg Pathol 8:899905.
  • Brusasco V., Crimi E., Gianiorio P., Lantero S., & Rossi G.A. (1990) Allergen-induced increase in airway responsiveness and inflammation in mild asthma. J Appl Physiol 69:220914.
  • Bullock E.D., Johnson E.M. Jr (1996) Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem 271:275008.
  • Butterworth A.E. (1984) Cell-mediated damage to helminths. Adv Parasitol 23:143235.
  • Butterworth A.E., Franks D. (1975) Nonspecific cytotoxic effects of antigen-transformed lymphocytes. III. Relationship to specific cytotoxicity. Cell Immunol 16:7481.
  • Caldwell J.H., Tennerbaum J.I., Bronstein H.A. (1975) Serum IgE to eosinophilic gastroenteritis. N Engl J Med 292:138890.
  • Capron M., Kusnierz J.P., Prin L. et al. (1985) Cytophilic IgE on human blood and tissue eosinophils: detection by flow micro-fluorometry. J Immunol 134:30138.
  • Capron M., Soussi Gounni A., Morita M. et al. (1995) Eosinophils: from low- to high-affinity immunoglobulin E receptors. Allergy 50 (25 suppl.):203.
  • Cardenas S., Auais A., & Piedimonte G. (2005) Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3:71926.
  • Cello J.P. (1979) Eosinophilic gastroenteritis: a complex disease entity. Am J Med 67:1097114.
  • Chae S.C., Park Y.R., Oh G.J., Lee J.H., & Chung H.T. (2005) The suggestive association of eotaxin-2 and eotaxin-3 gene polymorphisms in Korean population with allergic rhinitis. Immunogenetics 56:7604.
  • Cho J.Y., Miller M., Baek K.J. et al. (2004) Inhibition of airway remodeling in IL-5 deficient mice. J Clin Invest 113:55160.
  • Chusid M.J., Dale D.C., West B.C., & Wolff S.M. (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:127.
  • Clark K., Simson L., Newcombe N. et al. (2004) Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen. J Leukoc Biol 75:10019.
  • Cockcroft D.W., Ruffin R.E., Dolovich J., & Hargreave F.E. (1977) Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 7:50313.
  • Coffman R.L., Seymour B.W., Hudak S., Jackson J., & Rennick D. (1989) Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 245:30810.
  • Collins P.D., Marleau S., Griffiths-Johnson D.A., Jose P.J., & Williams T.J. (1995) Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 182:116974.
  • Cools J., DeAngelo D.J., Gotlib J. et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:120114.
  • Cools J., Quentmeier H., Huntly B.J. et al. (2004a) The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 103:28025.
  • Cools J., Stover E.H., Wlodarska I., Marynen P., & Gilliland D.G. (2004b) The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 11:517.
  • Cortes J., Ault P., Koller C. et al. (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:471416.
  • Coyle A.J., Ackerman S.J., & Irvin C.G. (1993) Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am Rev Respir Dis 147:896900.
  • Crimi E., Spanevello A., Neri M., Ind P.W., Rossi G.A., & Brusasco V. (1998) Dissociation between airway inflammation and airway responsiveness in allergic asthma. Am J Respir Crit Care Med 157:49.
  • Cromwell O., Moqbel R., Fitzharris P. et al. (1988) Leukotriene C4 generation from human eosinophils stimulated with IgG–Aspergillus fumigatus antigen immune complexes. J Allergy Clin Immunol 82:53543.
  • Cromwell O., Wardlaw A.J., Champion A., Moqbel R., Osei D., & Kay A.B. (1990) IgG-dependent generation of platelet-activating factor by normal and low density human eosinophils. J Immunol 145:38628.
  • Culley F.J., Pollott J., & Openshaw P.J. (2002) Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 196:13816.
  • Daffern P.J., Pfiefer P.H., Ember J.A., & Hugli T.E. (1995) C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181:211927.
  • Daugherty B.L., Siciliano S.J., Demartino J.A., Malkowitz L., Sirotina A., & Springer M.S. (1996) Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 183:234954.
  • Davis M.D., Plager D.A., George T.J., Weiss E.A., Gleich G.J., & Leiferman K.M. (2003) Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol 112:98894.
  • Dehlawi M.S., & Goyal P.K. (2003) Responses of inbred mouse strains to infection with intestinal nematodes. J Helminthol 77:11924.
  • De Jesus A.R., Magalhaes A., Miranda D.G. et al. (2004) Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun 72:33917.
  • De Koter R.P., & Singh H. (2000) Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288:143941.
  • Dent L.A., Strath M., Mellor A.L., & Sanderson C.J. (1990) Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 172:142531.
  • Denzler K.L., Borchers M.T., Crosby J.R. et al. (2001) Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol 167:167282.
  • Desreumaux P., Nutten S., & Colombel J.F. (1999) Activated eosinophils in inflammatory bowel disease: do they matter? Am J Gastroenterol 94:33968.
  • DeVincenzo J.P. (2005) Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J 24:S177S183.
  • Dimova-Yaneva D., Russell D., Main M., Brooker R.J., & Helms P.J. (2004) Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy 34:5558.
  • DiScipio R.G., Daffern P.J., Jagels M.A., Broide D.H., & Sriramarao P. (1999) A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162:112736.
  • Djukanovic R., Wilson J.W., Britten K.M. et al. (1990) Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 142:86371.
  • Domachowske J.B., Dyer K.D., Bonville C.A., & Rosenberg H.F. (1998) Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 177:145864.
  • Domachowske J.B., Bonville C.A., Dyer K.D., Easton A.J., & Rosenberg H.F. (2000a) Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. Cell Immunol 200:98104.
  • Domachowske J.B., Bonville C.A., Gao J.L., Murphy P.M., Easton A.J., & Rosenberg H.F. (2000b) The chemokine MIP-1α and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol 165:267782.
  • Dorman S.C., Sehmi R., Gauvreau G.M. et al. (2004a) Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 169:56572.
  • Dorman S.C., Efthimiadis A., Babirad I. et al. (2004b) Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis. Am J Respir Crit Care Med 169:5737.
  • Douwes J., Gibson P., Pekkanen J., & Pearce N. (2002) Noneosinophilic asthma: importance and possible mechanisms. Thorax 57:6438.
  • Du J., Stankiewicz M.J., Liu Y. et al. (2002) Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem 277:4348194.
  • Dubois G.R., Schweizer R.C., Versluis C., Bruijnzeel-Koomen C.A., & Bruijnzeel P.L. (1998) Human eosinophils constitutively express a functional interleukin-4 receptor: interleukin-4-induced priming of chemotactic responses and induction of PI-3 kinase activity. Am J Respir Cell Mol Biol 19:6919.
  • Durack D.T., Sumi S.M., & Klebanoff S.J. (1979) Neurotoxicity of human eosinophils. Proc Natl Acad Sci USA 76:14437.
  • Durcan N., Costello R.W., McLean W.G. et al. (2006) Eosinophilmediated cholinergic nerve remodelling. Am J Respir Cell Mol Biol 34:77586.
  • Dvorak A.M. (1980) Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vitro: cytotoxic potential in Crohn's disease. J Immunol 125:4602.
  • Easton A.J., Domachowske J.B., & Rosenberg H.F. (2007) Pneumonia virus of mice. In: CaneP., ed. Perspectives in Medical Virology, XXXX, XXXX, pp. 299319.
  • Ebisawa M., Schleimer R.P., Bickel C., & Bochner B.S. (1995) Phenotyping of purified human peripheral blood eosinophils using the blind panel mab. In: SchlossmanS.F., BoumsellL., GilksW. et al. eds. Leukocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York. pp. 10368.
  • Ebnet K., Kaldjian E.P., Anderson A.O., & Shaw S. (1996) Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol 14:15577.
  • Egan R.W., Athwahl D., Chou C.C. et al. (1995) Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Appl Immunol 107:3212.
  • Egesten A., Alumets J., Von Mecklenburg C., Palmegren M., & Olsson I. (1986) Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique. J Histochem Cytochem 34:1399403.
  • Elsner J., Petering H., Hochstetter R. et al. (1997) The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 27:28928.
  • Elsner J., Petering H., Kimmig D., Wells T.N., Proudfoot A.E., & Kapp A. (1999) The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 118:4625.
  • Elsner J., Dulkys Y., Gupta S. et al. (2005) Differential pattern of CCR1 internalization in human eosinophils: prolonged internalization by CCL5 in contrast to CCL3. Allergy 60:138693.
  • Evans C.M., Fryer A.D., Jacoby D.B., Gleich G.J., & Costello R.W. (1997) Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest 100:225462.
  • Everard M.L. (2006) The role of the respiratory syncytial virus in airway syndromes in childhood. Curr Allergy Asthma Rep 6:97102.
  • Feng D., Flaumenhaft R., Bandeira-Melo C., Weller P., & Dvorak A. (2001) Ultrastructural localization of vesicle-associated membrane protein(s) to specialized membrane structures in human pericytes, vascular smooth muscle cells, endothelial cells, neutrophils, and eosinophils. J Histochem Cytochem 49:293304.
  • Fischer E., Capron M., Prin L., Kusnierz J.P., & Kazatchkine M.D. (1986) Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol 97:297306.
  • Flood-Page P., Menzies-Gow A., Phipps S. et al. (2002) Reduction of tissue eosinophils in mild atopic asthmatics by an anti-IL-5 monoclonal antibody (mepolizumab) is associated with inhibition of tenascin deposition within the bronchial epithelium basement membrane. Am J Respir Crit Care Med 109:165.
  • Flood-Page P., Phipps S., Menzies-Gow A., Ong Y.E., & Kay A.B. (2003a) Effect of intravenous administration of an anti-IL-5 (mepolizumab) on allergen-induced tissue eosinophilia, the latephase allergic reaction and the expression of a marker of repair/remodeling in human atopic subjects. J Allergy Clin Immunol 111:S261.
  • Flood-Page P.T., Menzies-Gow A.N., Kay A.B., & Robinson D.S. (2003b) Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167:199204.
  • Flood-Page P., Menzies-Gow A., Phipps S. et al. (2003c) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:102936.
  • Forbes E., Hulett M., Ahrens R. et al. (2006) ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 80:33041.
  • Foster B., Percopo M., Lee N.A. et al. (2007) Differential recruitment and activation of NK cells in wild type and ΔdblGATA eosinophil lineage-ablated mice. (In review).
  • Foster P., Hogan S., Ramsay A., Matthaei K., & Young I. (1996) Interleukin-5 deficiency abolishes eosinophilia, airway hyperreactivityand lung damage in mouse asthma model. J Exp Med 183:195201.
  • Foster P., Mould A., Yang M. et al. (2001) Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev 179:17381.
  • Fox V.L., Nurko S., & Furuta G.T. (2002) Eosinophilic esophagitis. Gastrointest Endosc 56:26070.
  • Fredens K., Dahl R., & Venge P. (1982) The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol 70:3616.
  • Frigas E., Loegering D.A., & Gleich G.J. (1980) Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest 42:3543.
  • Fryer A.D., Stein L.H., Nie Z. et al. (2006) Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 116:22836.
  • Fujii M., Tanaka H., & Abe S. (2005) Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 128:314855.
  • Fulkerson P.C., Zhu H., Williams D.A., Zimmermann N., & Rothenberg M.E. (2005) CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood 106:43643.
  • Furuta G.T. (1998) Eosinophils in the esophagus: acid is not the only cause. J Pediatr Gastroenterol Nutr 26:46871.
  • Furuta G.T., Ackerman S.J., & Wershil B.K. (1995) The role of the eosinophil in gastrointestinal diseases. Curr Opin Gastroenterol 11:5417.
  • Furuta G.T., Nieuwenhuis E.E., Karhausen J. et al. (2005) Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am J Physiol 289:G890G897.
  • Gaddy J.N., Margolskee D.J., Bush R.K., Williams V.C., & Busse W.W. (1992) Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 146:35863.
  • Galli T., Zahraoui A., Vaidyanathan V.V. et al. (1998) A novel tetanus neurotoxin-insensitive vesicle-associated membrane protein in SNARE complexes of the apical plasma membrane of epithelial cells. Mol Biol Cell 9:143748.
  • Garofalo R., Kimpen J.L., Welliver R.C., & Ogra P.L. (1992) Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120:2832.
  • Garofalo R.P., Patti J., Hintz K.A., Hill V., Ogra P.L., & Welliver R.C. (2001) Macrophage inflammatory protein-1 alpha (not Thelper 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 184:3939.
  • Garrett J.K., Jameson S.C., Thomson B. et al. (2004) Antiinterleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:11519.
  • Gauthier M.C., Racine C., Ferland C. et al. (2003) Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils. Int J Biochem Cell Biol 35:166773.
  • Gauvreau G.M., Watson R.M., & O'Byrne P.M. (1999) Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 160:6407.
  • Georas S.N., Liu M.C., Newman W., Beall L.D., Stealey B.A., & Bochner B.S. (1992) Altered adhesion molecule expression and endothelial cell activation accompany the recruitment of human granulocytes to the lung after segmental antigen challenge. Am J Respir Cell Mol Biol 7:2619.
  • Georas S.N., McIntyre B.W., Ebisawa M. et al. (1993) Expression of a functional laminin receptor (alpha 6 beta 1, very late activation antigen-6) on human eosinophils. Blood 82:28729.
  • Giembycz M.A., & Lindsay M.A. (1999) Pharmacology of the eosinophil. Pharmacol Rev 51:213340.
  • Glauert A.M., & Butterworth A.E. (1977) Morphological evidence for the ability of eosinophils to damage antibody-coated schistosomula. Trans R Soc Trop Med Hyg 71:3925.
  • Gleich G.J., & Adolphson C.R. (1986) The eosinophilic leukocyte: structure and function. Adv Immunol 39:177253.
  • Gleich G.J., & Loegering D.A. (1984) Immunobiology of eosinophils. Annu Rev Immunol 2:42959.
  • Gleich G.J., Loegering D.A., & Maldonado J.E. (1973) Identification of a major basic protein in guinea pig eosinophil granules. J Exp Med 137:145971.
  • Gleich G.J., Loegering D.A., Bell M.P., Checkel J.L., Ackerman S.J., & McKean D.J. (1986) Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 83:314650.
  • Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., & Butterfield J.H. (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:15778.
  • Gombart A.F., Kwok S.H., Anderson K.L., Yamaguchi Y., Torbett B.E., & Koeffler H.P. (2003) Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU1. Blood 101:326573.
  • Gonzalo J.A., Lloyd C.M., Kremer L. et al. (1996) Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 98:233245.
  • Gonzalo J.A., Lloyd C.M., Wen D. et al. (1998) The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 188:15767.
  • Gouon-Evans V., & Pollard J.W. (2001) Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology 142:451521.
  • Gouon-Evans V., Rothenberg M.E., & Pollard J.W. (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127:226982.
  • Grayson M.H., Van der Vieren M., Sterbinsky S.A. et al. (1998) alphadbeta2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 188:218791.
  • Green R.H., Brightling C.E., McKenna S. et al. (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:171521.
  • Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., & Briesewitz R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 100:78305.
  • Guajardo J.R., Plotnick L.M., Fende J.M., Collins M.H., Putnam P.E., & Rothenberg M.E. (2002) Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry. J Pediatr 141:57681.
  • Gundel R.H., Letts L.G., & Gleich G.J. (1991) Human eosinophil major basic protein induces airways constriction and airway hyperresponsiveness in primates. J Clin Invest 87:14703.
  • Gupta S.K., Ross G.D., Good R.A., & Siegal F.P. (1976) Surface markers of human eosinophils. Blood 48:75563.
  • Guyot B., Valverde-Garduno V., Porcher C., & Vyas P. (2004) Deletion of the major GATA-1 enhancer HS1 does not affect GATA1 expression and eosinophil differentiation. Blood 104:8991.
  • Hagan P., Wilkins H.A., Blumenthal U.J., Hayes R.J., & Greenwood B.M. (1985) Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunol 7:62532.
  • Hahn C., Islamian A.P., Renz H., & Nockher A. (2006) Airway epithelial cells produce neutrophins and promote the survival of eosinophils during allergic airway inflammation. J Allergy Clin Immunol 117:78794.
  • Hamann K.J., Barker R.L., Loegering D.A., & Gleich G.J. (1987) Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol 73:5239.
  • Hamann K.J., Ten R.M., Loegering D.A. et al. (1990) Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily. Genomics 7:53546.
  • Hamann K.J., Barker R.L., Ten R.M., & Gleich G.J. (1991) The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol 94:2029.
  • Handzel Z.T., Busse W.W., Sedgwick J.B. et al. (1998) Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 160:127984.
  • Hansel T.T., Braunstein J.B., Walker C. et al. (1991) Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol 86:2717.
  • Harrison A.M., Bonville C.A., Rosenberg H.F., & Domachowske J.B. (1999) Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 159:191824.
  • Hartnell A., Moqbel R., Walsh G.M., Bradley B., & Kay A.B. (1990) Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. Immunology 69:26470.
  • Hartnell A., Kay A.B., & Wardlaw A.J. (1992) IFN-γ induces expression of FcγRIII (CD16) on human eosinophils. J Immunol 148:14718.
  • Haselden B.M., Kay A.B., & Larche M. (1999) Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189:188594.
  • Haskell M.D., Moy J.N., Gleich G.J., & Thomas L.L. (1995) Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein. Blood 86:462737.
  • Hastie A.T., Loegering D.A., Gleich G.J., & Kueppers F. (1987) The effect of purified human eosinophil major basic protein on mammalian ciliary activity. Am Rev Respir Dis 135:84853.
  • Hauber H.P., Bergeron C., & Hamid Q. (2004) IL-9 in allergic inflammation. Int Arch Allergy Immunol 134:7987.
  • Heil F., Hemmi H., Hochrein H. et al. (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:15269.
  • Henderson J.P., Byun J., Williams M.V. et al. (2001) Bromination of deoxycytidine by eosinophil peroxidase: a mechanism for mutagenesis by oxidative damage of nucleotide precursors. Proc Natl Acad Sci USA 98:16316.
  • Herndon F.J., & Kayes S.G. (1992) Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. J Immunol 149:36427.
  • Hibi T., Hirashima N., & Nakanishi M. (2000) Rat basophilic leukemia cells express syntaxin-3 and VAMP-7 in granule membranes. Biochem Biophys Res Commun 271:3641.
  • Hill S.M., & Milla P.J. (1990) Colitis caused by food allergy in infants. Arch Dis Child 65:1323.
  • Hirai H., Tanaka K., Yoshie O. et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:25561.
  • Hirai H., Zhang P., Dayaram T. et al. (2006) C/EBPβ, is required for emergency granulopoiesis. Nat Immunol 7:7329.
  • Hirasawa R., Shimizu R., Takahashi S. et al. (2002) Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 195:137986.
  • Hisamatsu K., Ganbo T., Nakazawa T. et al. (1990) Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro. J Allergy Clin Immunol 86:5263.
  • Hoffmann H.J., Bjerke T., Karawajczyk M., Dahl R., Knepper M.A., & Nielsen S. (2001) SNARE proteins are critical for regulated exocytosis of ECP from human eosinophils. Biochem Biophys Res Commun 280:1726.
  • Hogan S.P., Koskinen A., & Foster P.S. (1997) Interleukin-5 and eosinophils induce airway damage and bronchial hyperreactivity during allergic airway inflammation in BALB/c mice. Immunol Cell Biol 75:2848.
  • Hogan S.P., Mishra A., Brandt E.B. et al. (2001) A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2:35360.
  • Hogan S.P., Rothenberg M.E., Forbes E., Smart V.E., Matthaei K.I., & Foster P.S. (2004) Chemokines in eosinophil-associated gastrointestinal disorders. Curr Allergy Asthma Rep 4:7482.
  • Hokibara S., Takamoto M., Tominaga A., Takatsu K., & Sugane K. (1997) Marked eosinophilia in interleukin-5 transgenic mice fails to prevent Trichinella spiralis infection. J Parasitol 83:11869.
  • Horie S., Okubo Y., Hossain M. et al. (1997) Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med 36:17985.
  • Horigome K., Bullock E.D., & Johnson E.M. Jr. (1994) Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem 269:2695702.
  • Humbert M., Menz G., Ying S. et al. (1999) The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 20:52833.
  • Humbles A.A., Lu B., Friend D.S. et al. (2002) The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 99:147984.
  • Humbles A.A., Lloyd C.M., McMillan S.J. et al. (2004) A critical role for eosinophils in allergic airways remodeling. Science 305:17769.
  • Hunt L.W., Frigas E., Butterfield J.H. et al. (2004) Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol 113:8539.
  • Hussain A., Brown P.J., Thwaites B.C., & Hastings A.G. (1994) Eosinophilic endomyocardial disease due to high grade chest wall sarcoma. Thorax 49:10401.
  • Iacono G., Carroccio A., Cavataiio F. et al. (1996) Gastroesophageal reflux and cows milk allergy in infants: a prospective study. J Allergy Clin Immunol 97:8227.
  • Iredale M.J., Wanklyn S.A., Phillips I.P., Krausz T., & Ind P.W. (1994) Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clin Exp Allergy 24:9405.
  • Ishihara C., Ochiai K., Kagami M. et al. (1997) Human peripheral eosinophils express functional interferon-gamma receptors (IFNgammaR). Clin Exp Immunol 110:5249.
  • Iwama A., Osawa M., Hirasawa R. et al. (2002) Reciprocal roles for CCAAT/enhancer binding protein (C/EBP) and PU1 transcription factors in Langerhans cell commitment. J Exp Med 195:54758.
  • Jankovic D., Steinfelder S., Kullberg M.C., & Sher A. (2006) Mechanisms underlying helminth-induced Th2 polarization: default, negative or positive pathways? Chem Immunol Allergy 90:6581.
  • Jose P.J., Griffiths-Johnson D.A., Collins P.D. et al. (1994) Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 179:8817.
  • Kane G.C., Pollice M., Kim C.J. et al. (1996) A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 97:64654.
  • Kariyawasam H.H., Aizen M., Barkans J., Robinson D.S., & Kay A.B. (2007) Remodelling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma. Am J Respir Care Med 175:896904.
  • Kay A.B., Phipps S., & Robinson D.S. (2004) A role for eosinophils in airway remodelling in asthma. Trends Immunol 25:47782.
  • Kelly K.J., Lazenby A.J., Rowe P.C., Yardley J.H., Perman J.A., & Sampson H.A. (1995) Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 109:150312.
  • Keshavarzian A., Saverymuttu S.H., Tai P.C. et al. (1985) Activated eosinophils in familial eosinophilic gastroenteritis. Gastroenterology 88:10419.
  • Khan S., & Orenstein S.R. (2002) Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr Drugs 4:56370.
  • Khodoun M.V., Orekhova T., Potter C., Morris S., & Finkelman F.D. (2004) Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med 200:85770.
  • Kim C.K., Koh J.Y., Han T.H., Kim do K., Kim B.I., & Koh Y.Y. (2006) Increased levels of BAL cysteinyl leukotrienes in acute RSV bronchiolitis. Acta Paediatr 95:47985.
  • Kim J.T., Schimming A.W., & Kita H. (1999) Ligation of Fc gamma RII (CD32) pivotally regulates survival of human eosinophils. J Immunol 162:42539.
  • Kincade P.W. (2006) Supplying the demand for granulocytes. Nat Immunol 7:7012.
  • Kips J.C., O'Connor B.J., Langley S.J. et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:16559.
  • Kita H. (1996) The eosinophil: a cytokine-producing cell? J Allergy Clin Immunol 97:88992.
  • Kita H., & Gleich G.J. (1997) Eosinophils and IgE receptors: a continuing controversy. Blood 89:3497501.
  • Kita H., Abu-Ghazaleh R.I., Gleich G.J., & Abraham R.T. (1991) Regulation of Ig-induced eosinophil degranulation by adenosine 3′,5- cyclic monophosphate. J Immunol 146:271218.
  • Kita H., Kaneko M., Bartemes K.R. et al. (1999) Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 162:690111.
  • Klion A.D., & Nutman T.B. (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113:307.
  • Klion A.D., Noel P., Akin C. et al. (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:46606.
  • Klion A.D., Robyn J., Akin C. et al. (2004a) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:4738.
  • Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., & Nutman T.B. (2004b) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103:293941.
  • Klion A.D., Bochner B.S., Gleich G.J. et al. (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117:1292302.
  • Knopf P.M., Nutman T.B., & Reasoner J.A. (1977) Schistosoma mansoni resistance to reinfection in the rat. Exp Parasitol 41:7482.
  • Koenderman L., Kuijpers T.W., Blom M., Tool A.T., Roos D., & Verhoeven A.J. (1991) Characteristics of CR3-mediated aggregation in human eosinophils: effect of priming by platelet-activating factor. J Allergy Clin Immunol 87:94754.
  • Kopf M., Brombacher F., Hodgkin P.D. et al. (1996) IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:1524.
  • Korenaga M., Hitoshi Y., Yamaguchi N., Sato Y., Takatsu K., & Tada I. (1991) The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice. Immunology 72:5027.
  • Korsgren M., Erjefalt J.S., Korsgren O., Sundler F., & Persson C.G.A. (1997) Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J Exp Med 185:88592.
  • Kristjansson S., Bjarnarson S.P., Wennergren G. et al. (2005) Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol 116:80511.
  • Kuijpers T.W., Mul E.P., Blom M. et al. (1993) Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J Exp Med 178:27984.
  • Kunkel E.J., & Butcher E.C. (2002) Chemokines and the tissuespecific migration of lymphocytes. Immunity 16:14.
  • Lacy P., & Moqbel R. (1997) Eokines: synthesis, storage and release from human eosinophils. Mem Inst Oswaldo Cruz 92 (suppl.):H125H133.
  • Lacy P., & Moqbel R. (2000) Eosinophil cytokines. Chem Immunol 76:13455.
  • Lacy P., Thompson N., & Tian M. (1995) A survey of GTP-binding proteins and other potential key regulators of exocytotic secretion in eosinophils. Apparent absence of rab3 and vesicle fusion protein homologues. J Cell Sci 108:354756.
  • Lacy P., Mahmudi-Azer S., Bablitz B. et al. (1999) Rapid mobilization of intracellularly stored RANTES in response to interferon-γ in human eosinophils. Blood 94:2332.
  • Lacy P., Logan M.R., Bablitz B., & Moqbel R. (2001) Fusion protein vesicle-associated membrane protein 2 is implicated in IFNgamma-induced piecemeal degranulation in human eosinophils from atopic individuals. J Allergy Clin Immunol 107:6718.
  • Lacy P., Abdel Latif D., Steward M., Musat-Marcu S., Man S.F., & Moqbel R. (2003) Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects. J Immunol 170:26709.
  • Leckie M.J. (2003) Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2:24559.
  • Leckie M.J., Ten Brinke A., Khan J. et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:21448.
  • Lee J., McGarry M., Farmer S. et al. (1997) Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 185:214356.
  • Lee J.J., & Lee N.A. (2005) Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exp Allergy 35:615.
  • Lee J.J., Dimina D., Macias M.P. et al. (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305:17736.
  • Le Goff L., Loke P., Ali H.F., Taylor D.W., & Allen J.E. (2000) Interleukin-5 is essential for vaccine-mediated immunity but not innate resistance to a filarial parasite. Infect Immun 68:251317.
  • Lehrer R.I., Szklarek D., Barton A., Ganz T., Hamann K.J., & Gleich G.J. (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142:442834.
  • Lewis D.M., Lewis J.C., Loegering D.A., & Gleich G.J. (1978) Localization of the guinea pig eosinophil major basic protein to the core of the granule. J Cell Biol 77:70213.
  • Liacouras C.A., Wenner W.J., Brown K., & Ruchelli E. (1998) Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 26:3805.
  • Logan M.R., Lacy P., Bablitz B., & Moqbel R. (2002) Expression of eosinophil target SNAREs as potential cognate receptors for vesicle-associated membrane protein-2 in exocytosis. J Allergy Clin Immunol 109:299306.
  • Logan M.R., Odemuyiwa S.O., & Moqbel R. (2003) Understanding exocytosis in immune and inflammatory cells: the molecular basis of mediator secretion. J Allergy Clin Immunol 111:92332.
  • Logan M.R., Lacy P., Odemuyiwa S.O. et al. (2006) A critical role for vesicle-associated membrane protein-7 in exocytosis from human eosinophils and neutrophils. Allergy 61:77784.
  • Lopez A.F., Begley C.G., Williamson D.J., Warren D.J., Vadas M.A., & Sanderson C.J. (1986) Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med 163:108599.
  • Lopez A.F., Sanderson C.J., Gamble J.R., Campbell H.D., Young I.G., & Vadas M.A. (1988) Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 167:21924.
  • Lucey D.R., Nicholson W.A., & Weller P.F. (1989) Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci USA 86:134851.
  • Ma W., Bryce P.J., Humbles A.A. et al. (2002) CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 109:6218.
  • McDevitt M.A., Fujiwara Y., Shivdasani R.A., & Orkin S.H. (1997) An upstream DNaseI hypersensitive region of the hematopoieticexpressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice. Proc Natl Acad Sci USA 94:797681.
  • McGrogan M., Simonsen C., Scott R. et al. (1988) Isolation of a complementary DNA clone encoding a precursor to human eosinophil major basic protein. J Exp Med 168:2295308.
  • MacKenzie J.R., Mattes J., Dent L.A., & Foster P.S. (2001) Eosinophils promote allergic disease of the lung by regulating CD4+ Th2lymphocyte function. J Immunol 167:314655.
  • McLaren D.J., McKean J.R., Olsson I., Venges P., & Kay A.B. (1981) Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro. Parasite Immunol 3:35973.
  • McNagny K.M., & Graf T. (2002) Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 195:F43F47.
  • McNagny K.M., Sieweke M.H., Doderlein G., Graf T., & Nerlov C. (1998) Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1. EMBO J 17:366980.
  • Maddox D.E., Kephart G.M., Coulam C.B., Butterfield J.H., Benirschke K., & Gleich G.J. (1984) Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta. J Exp Med 160:2941.
  • Martin J.G., Siddiqui S., & Hassan M. (2006) Immune responses to viral infections: relevance to asthma. Paediatr Respir Rev 7 (suppl. 1):S125S127.
  • Matsumoto K., Schleimer R.P., Saito H., Iikura Y., & Bochner B.S. (1995) Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 86:143743.
  • Matsuyama G., Ochiai K., Ishihara C., Kagami M., Tomioka H., & Koya N. (1998) Heterogeneous expression of tumor necrosis factor-alpha receptors I and II on human peripheral eosinophils. Int Arch Allergy Immunol 117 (suppl. 1):2833.
  • Matthews A.N., Friend D.S., Zimmermann N. et al. (1998) Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci USA 95:62738.
  • Mauser P.J., Pitman A.M., Fernandez X. et al. (1995) Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 152:46772.
  • Mawhorter S.D., Kazura J.W., & Boom W.H. (1994) Human eosinophils as antigen-presenting cells: relative efficiency for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology 81:58491.
  • Mayeno A.N., Curran A.J., Roberts R.L., & Foote C.S. (1989) Eosinophils preferentially use bromide to generate halogenating agents. J Biol Chem 264:56608.
  • Meeusen E.N., & Balic A. (2000) Do eosinophils have a role in the killing of helminth parasites? Parasitol Today 16:95101.
  • Menzies-Gow A., Ying S., Sabroe I. et al. (2002) Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 169:271218.
  • Metcalf D. (1991) Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 254:52933.
  • Miller A.L., Bowlin T.L., & Lukacs N.W. (2004) Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 189:141930.
  • Mishra A., Hogan S.P., Lee J.J., Foster P.S., & Rothenberg M.E. (1999) Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 103:171927.
  • Mishra A., Hogan S.P., Brandt E.B., & Rothenberg M.E. (2000) Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. Blood 96:153844.
  • Mishra A., Hogan S.P., Brandt E.B. et al. (2002) Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem 277:440612.
  • Monteiro R.C., Hostoffer R.W., Cooper M.D., Bonner J.R., Gartland G.L., & Kubagawa H. (1993) Definition of immunoglobulin-A receptors on eosinophils and their enhanced expression in allergic individuals. J Clin Invest 92:16815.
  • Moon A., & Kleinman R.E. (1995) Allergic gastroenteropathy in children. Ann Allergy Asthma Immunol 74:512.
  • Moqbel R., & Lacy P. (1998) Eosinophil cytokines. In: BusseW.W., HolgateS.T., eds. Inflammatory Mechanisms in Asthma. Marcel Dekker, New York. pp. 22746.
  • Moser R., Fehr J., & Bruijnzeel P.L. (1992) IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 149:14328.
  • Mullock B.M., Smith C.W., Ihrke G. et al. (2000) Syntaxin 7 is localized to late endosome compartments, associates with Vamp 8, and is required for late endosome–lysosome fusion. Mol Biol Cell 11:313753.
  • Munitz A., & Levi-Schaffer F. (2007) Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel? J Allergy Clin Immunol 119:13827.
  • Munitz A., Bachelet I., Fraenkel S. et al. (2005) 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 174:11018.
  • Munitz A., Bachelet I., Eliashar R. et al. (2006) CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol 177:7783.
  • Murphy P.M. (1994) The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12:593633.
  • Nagase H., Miyamasu M., Yamaguchi M. et al. (2000) Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol 106:11329.
  • Nagase H., Okugawa S., Ota Y. et al. (2003) Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 171:397782.
  • Nakajima H., Sano H., Nishimura T., Yoshida S., & Iwamoto I. (1994) Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 179:114554.
  • Nakamura H., Luster A.D., Nakamura T. et al. (2001) Variant eotaxin: its effects on the asthma phenotype. J Allergy Clin Immunol 108:94653.
  • Nerlov C., & Graf T. (1998) PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 12:240312.
  • Nerlov C., McNagny K.M., Doderlein G., Kowenz-Leutz E., & Graf T. (1998) Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev 12:241323.
  • Nishitani H., Okabayashi M., Satomi M., Shimoyama T., & Dohi Y. (1998) Infiltration of peroxidase-producing eosinophils into the lamina propria of patients with ulcerative colitis. J Gastroenterol 33:18995.
  • Nutku E., Soussi Gounni A., Hazcku A. et al. (1999) Stimulation of IL-9 receptors on human eosinophils upregulates IL-5 rceptor mRNA expression. J Allergy Clin Immunol 103:S113.
  • Nutku E., Aizawa H., Hudson S.A., & Bochner B.S. (2003) Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101:501420.
  • O'Byrne P.M., Inman M.R., & Parameswaran K. (2001) The trials and tribulations of interleukin-5, eosinophils and allergic asthma. J Allergy Clin Immunol 108:5038.
  • Ochiai K., Ishihara C., & Tomioka H. (1999) Signal transduction through interferon-gamma receptor on human eosinophils. Int Arch Allergy Immunol 118:4436.
  • Odemuyiwa S.O., Ghahary A., Li Y. et al. (2004) Human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxyenase. J Immunol 173:590913.
  • O'Donnell M.C., Ackerman S.J., Gleich G.J., & Thomas L.L. (1983) Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med 157:198191.
  • Odze R.D., Wershil B.K., Leichtner A.M., & Antonioli D.A. (1995) Allergic colitis in infants. J Pediatr 126:16370.
  • Ohkawara Y., Lim K.G., Xing Z. et al. (1996) CD40 expression by human peripheral blood eosinophils. J Clin Invest 97:17616.
  • Ohno I., Ohtani H., Nitta Y. et al. (1997) Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 16:21219.
  • Ohshima N., Nagase H., Koshino T. et al. (2002) A functional study on CysLT(1) receptors in human eosinophils. Int Arch Allergy Immunol 129:6775.
  • Okada S., Kita H., George T.J., Gleich G.J., & Leiferman K.M. (1997) Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol Biol 17:51928.
  • Oliveira S.H., Lira S., Martinez A.C., Wiekowski M., Sullivan L., & Lukacs N.W. (2002) Increased responsiveness of murine eosinophils to MIP-1beta (CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8. J Leukoc Biol 71:101925.
  • Ollerenshaw S.L., & Woolcock A.J. (1992) Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 145:9227.
  • Onodera K., Takahashi S., Nishimura S. et al. (1997) GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and definitive erythropoiesis. Proc Natl Acad Sci USA 94:448792.
  • Openshaw P.J., & Tregoning J.S. (2005) Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18:54155.
  • O'Reilly M., Alpert R., Jenkinson S. et al. (2002) Identification of a histamine H4 receptor on human eosinophils: role in eosinophil chemotaxis. J Recept Signal Transduct Res 22:43148.
  • Owen W.F., Rothenberg M.E., Petersen J. et al. (1989) Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 170:3438.
  • Oyaizu N., Uemura Y., Izumi H., Morii S., Nishi M., & Hioki K. (1985) Eosinophilic gastroenteritis: immunohistochemical evidence for IgE mast cell-mediated allergy. Acta Pathol Jpn 35:75966.
  • Page S.M., Gleich G.J., Roebuck K.A., & Thomas L.L. (1999) Stimulation of neutrophil interleukin-8 production by eosinophil granule major basic protein. Am J Respir Cell Mol Biol 21:2307.
  • Paumet F., Le Mao J., Martin S. et al. (2000) Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment. J Immunol 164:58507.
  • Pearce E.J., Kane C., Sun J.J., Taylor J., McKee A.S., & Cervi L. (2004) Th2 response polarization during infection with the helminth parasite Schistosoma mansoni. Immunol Rev 201:11726.
  • Pearlman E., Hall L.R., Higgins A.W. et al. (1998) The role of eosinophils and neutrophils in helminth-induced keratitis. Invest Ophthalmol Vis Sci 39:117682. [Erratum appears in Invest Ophthalmol Vis Sci (1998) 39, 1641.].
  • Pégorier S., Wagner L.A., Gleich G.J., & Pretolani M. (2006) Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol 177:48619.
  • Peters M.S., Rodriguez M., & Gleich G.J. (1986) Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin by immunoelectron microscopy. Lab Invest 54:65662.
  • Phillips R.M., Stubbs V.E., Henson M.R., Williams T.J., Pease J.E., & Sabroe I. (2003) Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter. J Immunol 170:6190201.
  • Phipps S., Flood-Page P., Menzies-Gow A., Ong Y.E., & Kay A.B. (2004a) Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122:140612.
  • Phipps S., Benyahia F., Ou T.T., Barkans J., Robinson D.S., & Kay A.B. (2004b) Acute allergen-induced airway remodeling in atopic asthma. Am J Respir Cell Mol Biol 31:62632.
  • Phipps S., Lam C.E., Mahalingam S. et al. (2007) Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110:157886.
  • Piedra P.A. (2003) Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 22:S94S99.
  • Piliponsky A.M., Pickholtz D., Gleich G.J., & Levi-Schaffer F. (2001) Human eosinophils induce histamine release from antigenactivated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J Allergy Clin Immunol 107:9931000.
  • Piliponsky A., Gleich G., Bar I., & Levi-Schaffer F. (2002) Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol 38:1369.
  • Plager D.A., Loegering D.A., Checkel J.L. et al. (2006) Major basic protein homolog (MBP2): a specific human eosinophil marker. J Immunol 177:73405.
  • Plotz S.G., Lentschat A., Behrendt H. et al. (2001) The interaction of human peripheral blood eosinophils with bacterial lipopolysaccharide is CD14 dependent. Blood 97:23541.
  • Polgar J., Chung S.H., & Reed G.L. (2002) Vesicle-associated membrane protein 3 (VAMP-3) and VAMP-8 are present in human platelets and are required for granule secretion. Blood 100:10813.
  • Ponath P.D., Qin S., Post T.W. et al. (1996) Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183:243748.
  • Pope S.M., Fulkerson P.C., Blanchard C. et al. (2005a) Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J Biol Chem 280:1395261.
  • Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., & Rothenberg M.E. (2005b) The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 175:534150.
  • Popken-Harris P., Checkel J., Loegering D. et al. (1998) Regulation and processing of a precursor form of eosinophil granule major basic protein (ProMBP) in differentiating eosinophils. Blood 92:62331.
  • Powell W.S., Chung D., & Gravel S. (1995) 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol 154:412332.
  • Pretolani M., Ruffie C., Lapa e Silva J.R., Joseph D., Lobb R.R., & Vargaftig B.B. (1994) Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med 180:795805.
  • Rand T.H., Lopez A.F., Gamble J.R., & Vadas M.A. (1988) Nedocromil sodium and cromolyn (sodium cromoglycate) selectively inhibit antibody-dependent granulocyte-mediated cytotoxicity. Int Arch Allergy Appl Immunol 87:1518.
  • Rand T.H., Silberstein D.S., Kornfeld H., & Weller P.F. (1991) Human eosinophils express functional interleukin 2 receptors. J Clin Invest 88:82532.
  • Randolph A.G., & Wang E.E. (1996) Ribavirin for respiratory synctial virus lower respiratory tract infection. A systemic overview. Arch Pediatr Adolesc Med 150:9427.
  • Rankin S.M., Conroy D.M., & Williams T.J. (2000) Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 6:207.
  • Rao S.K., Huynh C., Proux-Gillardeaux V., Galli T., & Andrews N.W. (2004) Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis. J Biol Chem 279:204719.
  • Ravichandran V., Chawla A., & Roche P.A. (1996) Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. J Biol Chem 271:133003.
  • Redier H., Chanez P., De V.C. et al. (1992) Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 90:21524.
  • Reiman R.M., Thompson R.W., Feng C.G. et al. (2006) Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun 74:14719.
  • Rohrbach M.S., Wheatley C.L., Slifman N.R., & Gleich G.J. (1990) Activation of platelets by eosinophil granule proteins. J Exp Med 172:12714.
  • Romano M., Patriarca P., Melo C., Baralle F.E., & Dri P. (1994) Hereditary eosinophil peroxidase deficiency: immunochemical and spectroscopic studies and evidence for a compound heterozygosity of the defect. Proc Natl Acad Sci USA 91:12496500.
  • Rosenberg H.F., & Domachowske J.B. (2001) Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol 70:6918.
  • Rosenberg H.F., Ackerman S.J., & Tenen D.G. (1989) Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 170:16376.
  • Rosenberg H.F., Dyer K.D., Tiffany H.L., & Gonzalez M. (1995) Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet 10:21923.
  • Rosenberg H.F., Bonville C.A., Easton A.J., & Domachowske J.B. (2005) The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol Ther 105:16.
  • Rossetto O., Gorza L., Schiavo G., Schiavo N., Scheller R.H., & Montecucco C. (1996) VAMP/synaptobrevin isoforms 1 and 2 are widely and differentially expressed in nonneuronal tissues. J Cell Biol 132:16779.
  • Rothenberg M.E. (1998) Eosinophilia. N Engl J Med 338:1592600.
  • Rothenberg M.E., & Hogan S.P. (2006) The eosinophil. Annu Rev Immunol 24:14774.
  • Rothenberg M.E., Pomerantz J.L., Owen W.F. et al. (1988) Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem 263:139018.
  • Rothenberg M.E., Luster A.D., Lilly C.M., Drazen J.M., & Leder P. (1995) Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med 181:121116.
  • Rothenberg M.E., MacLean J.A., Pearlman E., Luster A.D., & Leder P. (1997) Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 185:78590.
  • Rothenberg M.E., Mishra A., Brandt E.B., & Hogan S.P. (2001a) Gastrointestinal eosinophils in health and disease. Adv Immunol 78:291328.
  • Rothenberg M.E., Mishra A., Collins M.H., & Putnam P.E. (2001b) Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol 108:8914.
  • Rothenberg M.E., Mishra A., Brandt E.B., & Hogan S.P. (2001c) Gastrointestinal eosinophils. Immunol Rev 179:13955.
  • Roufosse F., Cogan E., & Goldman M. (2003) The hypereosinophilic syndrome revisited. Annu Rev Med 54:16984.
  • Saavedra-Delgado A.M., & Metcalfe D.D. (1985) Interactions between food antigens and the immune system in the pathogenesis of gastrointestinal diseases. Ann Allergy 55:694702.
  • Sabroe I., Jones E.C., Usher L.R., Whyte M.K., & Dower S.K. (2002) Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 168:470110.
  • Saito T., Deskin R.W., Casola A. et al. (1997) Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. J Infect Dis 175:497504.
  • Sampson H.A. (1997) Food allergy. JAMA 278:188894.
  • Sampson H.A. (1999) Food allergy: Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol 103:71728.
  • Sanderson C.J. (1992) Interleukin-5, eosinophils, and disease. Blood 79:31019.
  • Sarin S.K., Malhotra V., Sen Gupta S., Karol A., Gaur S.K., & Anand B.S. (1978) Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 32:3637.
  • Sasaki O., Sugaya H., Ishida K., & Yoshimura K. (1993) Ablation of eosinophils with anti-IL-5 antibody enhances the survival of intracranial worms of Angiostrongylus cantonensis in the mouse. Parasite Immunol 15:34954.
  • Schaller J.L., & Burkland G.A. (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3:9.
  • Schaller M., Hogaboam C.M., Lukacs N., & Kunkel E.J. (2006) Respiratory viral infections drive chemokine expression and excerbate the asthmatic response. J Allergy Clin Immunol 118:295302.
  • Schleimer R.P., & Bochner B.S. (1994) The effect of glucocorticoids on human eosinophils. J Allergy Clin Immunol 94:120213.
  • Schwingshackl A., Duszyk M., Brown N., & Moqbel R. (1999) Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-α. J Allergy Clin Immunol 104:9839.
  • Scudamore H.H., Phillips S.F., Swedlund H.A., & Gleich G.J. (1982) Food allergy manifested by eosinophilia, elevated immunoglobulin E level, and protein-losing enteropathy: the syndrome of allergic gastroenteropathy. J Allergy Clin Immunol 70:12936.
  • Sedgwick J.B., Calhoun W.J., Vrtis R.F., Bates M.E., McAllister P.K., & Busse W.W. (1992) Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 149:371018.
  • Seminario M.C., Saini S.S., MacGlashan D.W. Jr., & Bochner B.S. (1999) Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol 162:6893900.
  • Shen Z., Wu W., & Hazen S.L. (2000) Activated leukocytes oxidatively damage DNA RNA, and the nucleotide pool through halide-dependent formation of hydroxyl radical. Biochemistry 39:547482.
  • Shenoy N.G., Gleich G.J., & Thomas L.L. (2003) Eosinophil major basic protein stimulates neutrophil superoxide production by a class IA phosphoinositide 3-kinase and protein kinase C-zetadependent pathway. J Immunol 171:373441.
  • Sher A., Coffman R.L., Hieny S., & Cheever A.W. (1990a) Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 145:391116.
  • Sher A., Coffman R.L., Hieny S., Scott P., & Cheever A.W. (1990b) Interleukin-5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci USA 87:615.
  • Sherman M.P., & Cox K.L. (1982) Neonatal eosinophilic colitis. J Pediatr 100:5879.
  • Shi H. (2004) Eosinophils function as antigen-presenting cells. J Leukoc Biol 76:5207.
  • Shi H.Z., Humbles A., Gerard C., Jin Z., & Weller P.F. (2000) Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 105:94553.
  • Shi H.Z., Xiao C.Q., Li C.Q. et al. (2004) Endobronchial eosinophils preferentially stimulate T helper cell type 2 responses. Allergy 59:42835.
  • Shinagawa K., & Kojima M. (2003) Mouse model of airway remodeling: strain differences. Am J Respir Crit Care Med 168:95967.
  • Shinkai A., Yoshisue H., Koike M. et al. (1999) A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 163:160210.
  • Shinkai K., Mohrs M., & Locksley R.M. (2002) Helper T cells regulate type-2 innate immunity in vivo. Nature 420:8259.
  • Shiraishi Y., Asano K., Nakajima T. et al. (2005) Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther 312:95460.
  • Sihra B.S., Kon O.M., Durham S.R., Walker S., Barnes N.C., & Kay A.B. (1997) Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 52:44752.
  • Simon H.U., Plotz S.G., Dummer R., & Blaser K. (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:111220.
  • Singh A.M., Moore P.E., Gern J.E., Lemanske R.F. Jr., & Hartert T.V. (2007) Bronchiolitis to asthma. A review and call for studies of gene–viral interactions in asthma causation. Am J Crit Care Med 175:10819.
  • Slifman N.R., Loegering D.A., McKean D.J., & Gleich G.J. (1986) Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 137:291317.
  • Slungaard A., & Mahoney J.R. (1991) Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. Implications for cytotoxicity. J Biol Chem 266:490310.
  • Snyman J.R., Sommers D.K., Gregorowski M.D., & Boraine H. (1992) Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: a comparative study. Eur J Clin Pharmacol 42:35962.
  • Sollner T., Whiteheart S.W., Brunner M. et al. (1993) SNAP receptors implicated in vesicle targeting and fusion. Nature 362:31824.
  • Solomon A., Aloe L., Pe'er J., Frucht-Pery J., Bonini S., & Levi-Schaffer F. (1998) Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 102:45460.
  • Someya A., Nishijima K., Nunoi H., Irie S., & Nagaoka I. (1997) Study on the superoxide-producing enzyme of eosinophils and neutrophils: comparison of the NADPH oxidase components. Arch Biochem Biophys 345:20713.
  • Spergel J.M., Beausoleil J.L., Mascarenhas M., & Liacouras C.A. (2002) The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 109:3638.
  • Spry C.J.F. (1988); Eosinophils. A Comprehensive Review and Guide to the Scientific and Medical Literature. Oxford Medical Publications, Oxford.
  • Sriramarao P., Von Andrian U.H., Butcher E.C., Bourdon M.A., & Broide D.H. (1994) L-selectin and very late antigen-4 integrin promote eosinophil rolling at physiological shear rates in vivo. J Immunol 153:423846.
  • Steegmaier M., Klumperman J., Foletti D.L., Yoo J.S., & Scheller R.H. (1999) Vesicle-associated membrane protein 4 is implicated in trans-Golgi network vesicle trafficking. Mol Biol Cell 10:195772.
  • Stein M.L., Collins M.H., Villanueva J.M. et al. (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118:131219.
  • Stellato C., Matsukura S., Fal A. et al. (1999) Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 163:562432.
  • Sturrock R.F., Kimani R., Cottrell B.J. et al. (1983) Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni. Trans R Soc Trop Med Hyg 77:36371.
  • Sturrock R.F., Kariuki H.C., Thiongo F.W. et al. (1996) Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Trans R Soc Trop Med Hyg 90:4854.
  • Sullivan S.K., McGrath D.A., Liao F., Boehme S.A., Farber J.M., & Bacon K.B. (1999) MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK). J Leukoc Biol 66:67482.
  • Sutton R.B., Fasshauer D., Jahn R., & Brunger A.T. (1998) Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395:34753.
  • Swartz J.M., Dyer K.D., Cheever A.W. et al. (2006) Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 108:24207.
  • Symon F.A., Lawrence M.B., Williamson M.L., Walsh G.M., Watson S.R., & Wardlaw A.J. (1996) Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol 157:171119.
  • Tachimoto H., & Bochner B.S. (2000) The surface phenotype of human eosinophils. Chem Immunol 76:4562.
  • Tachimoto H., Ebisawa M., & Bochner B.S. (2002) Cross-talk between integrins and chemokines that influences eosinophil adhesion and migration. Int Arch Allergy Immunol 128 (suppl. 1):1820.
  • Takamoto M., Ovington K.S., Behm C.A., Sugane K., Young I.G., & Matthaei K.I. (1997) Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57Bl/6 mice genetically deficient in IL-5. Immunology 90:51117.
  • Takatsu K., Takaki S., & Hitoshi Y. (1994) Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv Immunol 57:4590.
  • Tamura N., Ishii N., Nakazawa M. et al. (1996) Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Scand J Immunol 44:22938.
  • Tanaka H., Komai M., Nagao K. et al. (2004) Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 31:628.
  • Tatar M., Petriskova J., Zucha J. et al. (2005) Induced sputum eosinophils, bronchial reactivity, and cough sensitivity in subjetcs with allergic rhinitis. J Physiol Pharmacol 56 (suppl. 4):22736.
  • Ten R.M., Pease L.R., McKean D.J., Bell M.P., & Gleich G.J. (1989) Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med 169:175769.
  • Tenen D.G., Hromas R., Licht J.D., & Zhang D.E. (1997) Transcription factors, normal myeloid development and leukemia. Blood 90:489519.
  • Thivierge M., Doty M., Johnson J., Stankova J., & Rola-Pleszczynski M. (2000) IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol 165:52216.
  • Thomas E.L., Bozeman P.M., Jefferson M.M., & King C.C. (1995) Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. Formation of bromamines. J Biol Chem 270:290613.
  • Throsby M., Herbelin A., Pleau J.M., & Dardenne M. (2000) CD11c+ eosinophils in the murine thymus: developmental regulation and recruitment upon MHC class I-restricted thymocyte deletion. J Immunol 165:196575.
  • Tominaga A., Takaki S., Koyama N. et al. (1991) Transgenic mice expressing a B cell growth and differentiation factor (interleukin 5) develop eosinophilia and autoantibody production. J Exp Med 173:42939.
  • Tong J., Bandulwaia H.S., Clay B.S. et al. (2006) Fas-positive T cells regulate the resolution of airway inflammation in murine model of asthma. J Exp Med 203:117384.
  • Torpier G., Colombel J.F., Mathieu-Chandelier C. et al. (1988) Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol 74:4048.
  • Tripp R.A. (2004) Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17:16581.
  • Uchida D.A., Ackerman S.J., Coyle A.J. et al. (1993) The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo. A comparison with polycations. Am Rev Respir Dis 147:9828.
  • Vadas M., Lopez A., Gamble J. et al. (1994) Cytokines and allergy. J Allergy Clin Immunol 94:128993.
  • Van Dijk T.B., Caldenhoven E., Raaijmakers J.A., Lammers J.W., Koenderman L., & De Groot R.P. (1998) The role of transcription factor PU1 in the activity of the intronic enhancer of the eosinophil-derived neurotoxin (RNS2) gene. Blood 91:212632.
  • Van Rijt L.S., Vos N., Hijdra D., De Vries V.C., Hoogsteden H.C., & Lambrecht B.N. (2003) Airways eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T-cells. J Immunol 171:33728.
  • Voehringer D., Shinkai K., & Locksley R.M. (2004) Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 20:26777.
  • Von Andrian U.H., & Engelhardt B. (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348:6872.
  • Wallen N., Kita H., Weiler D., & Gleich G.J. (1991) Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 147:34905.
  • Walsh G.M. (2001) Eosinophil granule proteins and their role in disease. Curr Opin Hematol 8:2833.
  • Walsh G.M., Hartnell A., Moqbel R. et al. (1990) Receptor expression and functional status of cultured human eosinophils derivedfrom umbilical cord blood mononuclear cells. Blood 76:10511.
  • Walsh G.M., Williamson M.L., Symon F.A., Willars G.B., & Wardlaw A.J. (1996) Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colonystimulating factor. Blood 87:281521.
  • Walsh R.E., & Gaginella T.S. (1991) The eosinophil in inflammatory bowel disease. Scand J Gastronenterol 26:121724.
  • Walsh S.V., Antonioli D.A., Goldman H. et al. (1999) Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol 23:3906.
  • Wang H., Tan X., Chang H., Huang W., Gonzalez-Crussi F., & Hsueh W. (1999) Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora. Immunology 97:44754.
  • Wang J., & Slungaard A. (2006) Role of eosinophil peroxidase in host defense and disease pathology. Arch Biochem Biophys 445:25660.
  • Ward D.M., Pevsner J., Scullion M.A., Vaughn M., & Kaplan J. (2000) Syntaxin 7 and VAMP-7 are soluble N-ethylmaleimidesensitive factor attachment protein receptors required for late endosome–lysosome and homotypic lysosome fusion in alveolar macrophages. Mol Biol Cell 11:232733.
  • Wardlaw A.J. (1999) Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol 104:91726.
  • Wardlaw A.J. (2000) The role of adhesion in eosinophil function. Chem Immunol 78:93111.
  • Wardlaw A.J., Walsh G.M., & Symon F.A. (1994) Mechanisms of eosinophil and basophil migration. Allergy 49:797807.
  • Wasmoen T.L., Bell M.P., Loegering D.A., Gleich G.J., Prendergast F.G., & McKean D.J. (1988) Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. J Biol Chem 263:1255963.
  • Weg V.B., Williams T.J., Lobb R.R., & Nourshargh S. (1993) A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med 177:5616.
  • Wegner C.D., Gundel R.H., Reilly P., Haynes N., Letts L.G., & Rothlein R. (1990) Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 247:4569.
  • Weigmann M., Goggel R., Sei S. et al. (2007) Effect of a low molecular weight CCR-3 antagonist on chronic experimental asthma. Am J Respir Cell Mol Biol 36:617.
  • Weiler J.M., Edens R.E., & Gleich G.J. (1992) Eosinophil granule cationic proteins regulate complement. I. Activity on the alternative pathway. J Immunol 149:6438.
  • Weiler J.M., Edens R.E., Bell C.S., & Gleich G.J. (1995) Eosinophil granule cationic proteins regulate the classical pathway of complement. Immunology 84:21319.
  • Weiss S.J., Test S.T., Eckmann C.M., Roos D., & Regiani S. (1986) Brominating oxidants generated by human eosinophils. Science 234:2003.
  • Weller P.F. (1994) Eosinophils: structure and functions. Curr Opin Immunol 6:8590.
  • Weller P.F., Rand T.H., Barrett T., Elovic A., Wong D.T., & Finberg R.W. (1993) Accessory cell function of human eosinophils. HLADR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol 150:255462.
  • Wiehler S., Cuvelier S.L., Chakrabarti S., & Patel K.D. (2004) p38 MAP kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 315:46370.
  • Winter H.S., Madara J.L., Stafford R.J., Grand R.J., Quinlan J.E., & Goldman H. (1982) Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology 83:81823.
  • Woerly G., Roger N., Loiseau S., Dombrowicz D., Capron A., & Capron M. (1999) Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin A complexes. J Exp Med 190:48795.
  • Wynn T.A., Thompson R.W., Cheever A.W., & Mentink-Kane M. (2004) Immunopathogenesis of schistosomiasis. Immunol Rev 201:15667.
  • Yamada Y., Rothenberg M.E., Lee A.W. et al. (2006) The FIP1L1–PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107:40719.
  • Yamanaka R., Barlow C., Lekstrom-Himes J. et al. (1997) Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci USA 94:1318792.
  • Ying S., Barata L.T., Meng Q. et al. (1998) High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen-induced late-phase cutaneous reactions in atopic subjects. Immunology 93:2818.
  • Yoshida T., Naganuma T., Niizawa M., Kakizaki Y., Zeniya A., & Masamune O. (1995) [A case of eosinophilic gastroenteritis accompanied by perimyocarditis, which was strongly suspected.]. Nippon Shokakibyo Gakkai Zasshi 92:11838.
  • Yoshida T., Ikuta K., Sugaya H. et al. (1996) Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Ra-deficient mice. Immnity 4:48394.
  • You D., Becnel D., Wang K., Ripple M., Daly M., & Cormier S.A. (2006) Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway responses in adults. Respir Res 7:107.
  • Young J.D., Peterson C.G., Venge P., & Cohn Z.A. (1986) Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321:61316.
  • Yu C., Cantor A.B., Yang H. et al. (2002) Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 195:138795.
  • Yuan Q., Austen K.F., Friend D.S., Heidtman M., & Boyce J.A. (1997) Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 186:31323.
  • Zeck-Kapp G., & Kapp A. (1995) Subcellular mechanisms of eosinophil degranulation: the role of RANTES, interleukin-5 and tumor necrosis factor-alpha. Int Arch Allergy Immunol 107:345.
  • Zeck-Kapp G., Czech W., & Kapp A. (1994) TNF alpha-induced activation of eosinophil oxidative metabolism and morphology: comparison with IL-5. Exp Dermatol 3:17688.
  • Zeng Q., Subramaniam V.N., Wong S.H. et al. (1998) A novel synaptobrevin/VAMP homologous protein (VAMP5) is increased during in vitro myogenesis and present in the plasma membrane. Mol Biol Cell 9:242337.
  • Zhang D.E., Zhang P., Wang N.D., Hetherington C.J., Darlington G.J., & Tenen D.G. (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94:56974.
  • Zhao J., Takamura M., Yamaoka A., Odajima Y., & Iikura Y. (2002) Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. Pediatr Allergy Immunol 13:4750.
  • Zheutlin L.M., Ackerman S.J., Gleich G.J., & Thomas L.L. (1984) Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 133:21805.
  • Zhu J., & Emerson S.G. (2002) Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 21:3295313.
  • Zhu Z., Zheng T., Homer R.J. et al. (2004) Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304:167882.
  • Zimmermann N., Daugherty B.L., Kavanaugh J.L., El-Awar F.Y., Moulton E.A., & Rothenberg M.E. (2000a) Analysis of the CC chemokine receptor 3′ gene reveals a complex 5′ exon organization, a functional role for untranslated exon 1, and a broadly active promoter with eosinophil-selective elements. Blood 96:234654.
  • Zimmermann N., Hogan S.P., Mishra A. et al. (2000b) Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. J Immunol 165:583946.
  • Zimmermann N., Hershey G.K., Foster P.S., & Rothenberg M.E. (2003) Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 111:22742.
  • Zinchuk O., Fukushima A., Zinchuk V., Fukata K., & Ueno H. (2005) Direct action of platelet activating factor (PAF) induces eosinophil accumulation and enhances expression of PAF receptors in conjunctivitis. Mol Vis 11:11423.